Sana Biotechnology Announces Pricing of Public Offering
- SEATTLE, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA) (“Sana”), a company focused on changing the possible for patients through engineered cells, today announced that it has priced its underwritten public offering of 20,895,522 shares of its common stock at a price to the public of $3.35 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,492,537 shares of common stock at a price to the public of $3.3499 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.0001 per share exercise price for each pre-funded warrant. All of the shares and pre-funded warrants are to be sold by Sana. In addition, Sana has granted the underwriters a 30-day option to purchase up to an additional 3,358,208 shares of its common stock. The gross proceeds from the offering are expected to be approximately $75.0 million before deducting underwriting discounts and commissions and other offering expenses and excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on or about August 8, 2025, subject to satisfaction of customary closing conditions.
- 08/06/2025
|
Sana Biotechnology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
- SEATTLE, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA) (“Sana”), a company focused on changing the possible for patients through engineered cells, today announced that it has commenced an underwritten public offering of $75.0 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. In addition, Sana intends to grant the underwriters a 30-day option to purchase up to an additional $11.25 million of shares of its common stock. All of the shares of common stock and pre-funded warrants to be sold in the proposed offering will be sold by Sana. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering.
- 08/06/2025
|
Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates
- Following FDA input, Seres submitted Phase 2 study protocol to FDA for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) to treat hematological malignancies Seres engaging with multiple parties regarding various deal structures, including potential business development and partnerships, intended to secure capital and other resources to enable the clinical advancement of SER-155 and additional live biotherapeutic product candidates Seres received the $25 million installment payment, as expected, from Nestlé Health Science in July 2025 Conference call at 8:30 a.m. ET today CAMBRIDGE, Mass.
- 08/06/2025
|
Sana Biotechnology Announces Publication in New England Journal of Medicine of Groundbreaking Clinical Data from Transplantation Without Immunosuppression of Hypoimmune-Modified, Insulin-Producing Islet Cells in Patient with Type 1 Diabetes
- Data Demonstrate that Sana's Hypoimmune (HIP)-Modified Pancreatic Islet Cells, Transplanted with No Immunosuppression, Persist and Function Over Time in Patient with Type 1 Diabetes
- 08/04/2025
|
Sana Biotechnology Announces Positive Six-Month Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression
- Groundbreaking First-in-Human Study Establishes Potential to Treat Type 1 Diabetes by Transplanting Insulin-Secreting Cells Without Immunosuppression
- 06/23/2025
|
Sana Biotechnology Announces Invited Oral Presentation at the 85th Annual American Diabetes Association Scientific Sessions
- Presentation to highlight updated six-month clinical results of a hypoimmune-modified primary pancreatic islet cell therapy for patients with type 1 diabetes Presentation to highlight updated six-month clinical results of a hypoimmune-modified primary pancreatic islet cell therapy for patients with type 1 diabetes
- 06/09/2025
|
Sana Biotechnology to Present at June 2025 Investor Conferences
- SEATTLE, May 28, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in June. The presentations will feature a business overview and update.
- 05/28/2025
|
Securities Lawsuit Alert: Sana Biotechnology, Inc. (SANA) - Contact Levi & Korsinsky Before May 20, 2025
- NEW YORK, NY / ACCESS Newswire / May 20, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=149443&wire=1&utm_campaign=3 or contact Joseph E. Levi, Esq.
- 05/20/2025
|
SANA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sana Biotechnology, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
- NEW YORK, May 20, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sana Biotechnology, Inc. (“Sana” or “the Company”) (NASDAQ: SANA) and certain of its officers.
- 05/20/2025
|
Lost Money on Sana Biotechnology, Inc. (SANA)? Join Class Action Before May 20, 2025 - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESS Newswire / May 20, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=149393&wire=1&utm_campaign=23 or contact Joseph E. Levi, Esq.
- 05/20/2025
|
SANA DEADLINE TODAY: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Sana Biotechnology, Inc. Investors to Secure Counsel Before Important May 20 Deadline in Securities Class Action - SANA
- NEW YORK, NY / ACCESS Newswire / May 20, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sana Biotechnology, Inc. (NASDAQ:SANA) between March 17, 2023 and November 4, 2024, inclusive (the "Class Period"), of the important May 20, 2025 lead plaintiff deadline. SO WHAT: If you purchased Sana securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 05/20/2025
|
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers - SANA
- NEW YORK , May 20, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ: SANA) and certain officers. The class action, filed in the United States District Court for the Western District of Washington, and docketed under 25-cv-00512, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against Sana and certain of its top officials.
- 05/20/2025
|
Lost Money on Sana Biotechnology, Inc. (SANA)? Contact Levi & Korsinsky to Join Class Action Before May 20, 2025
- NEW YORK, NY / ACCESS Newswire / May 20, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=149338&wire=1&utm_campaign=20 or contact Joseph E. Levi, Esq.
- 05/20/2025
|
SANA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sana Biotechnology, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESS Newswire / May 20, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ:SANA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period").
- 05/20/2025
|
Levi & Korsinsky Notifies Shareholders of Sana Biotechnology, Inc.(SANA) of a Class Action Lawsuit and an Upcoming Deadline
- NEW YORK , May 20, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sana Biotechnology, Inc. investors who were adversely affected by alleged securities fraud between March 17, 2023 and November 4, 2024.
- 05/20/2025
|
SANA LAWSUIT ALERT: Levi & Korsinsky Notifies Sana Biotechnology, Inc. Investors - Lead Plaintiff Deadline May 20, 2025
- NEW YORK, NY / ACCESS Newswire / May 19, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=149279&wire=1&utm_campaign=7 or contact Joseph E. Levi, Esq.
- 05/19/2025
|
SANA DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Sana Biotechnology, Inc. Investors to Secure Counsel Before Important May 20 Deadline in Securities Class Action - SANA
- NEW YORK, NY / ACCESS Newswire / May 19, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sana Biotechnology, Inc. (NASDAQ:SANA) between March 17, 2023 and November 4, 2024, inclusive (the "Class Period"), of the important May 20, 2025 lead plaintiff deadline. SO WHAT: If you purchased Sana securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 05/19/2025
|
Sana: HIP-Modified Islet Cells To Possibly Change Scope Of Type 1 Diabetes Treatment
- Data from phase 1 studies using SC291 to treat patients with B-cell mediated autoimmune disorders and SC262 for patients with relapsed/refractory B-cell malignancies expected in 2025. First-in-human study using UP421 as a HIP-modified primary islet cell therapy to treat patients with Type 1 Diabetes established increase circulating C-peptide biomarker and without need of immunosuppressive therapy. An IND filing to initiate a phase 1 study using SC451 for the treatment of patients with Type 1 Diabetes, expected in 2026.
- 05/19/2025
|
Class Action Filed Against Sana Biotechnology, Inc. (SANA) Over Securities Violations - Contact Levi & Korsinsky Today
- NEW YORK, NY / ACCESS Newswire / May 19, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=149245&wire=1&utm_campaign=29 or contact Joseph E. Levi, Esq.
- 05/19/2025
|
Shareholders of Sana Biotechnology, Inc. Should Contact Levi & Korsinsky Before May 20, 2025 to Discuss Your Rights – SANA
- NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit.
- 05/19/2025
|
SANA DEADLINE TOMORROW: ROSEN, LEADING INVESTOR COUNSEL, Encourages Sana Biotechnology, Inc. Investors to Secure Counsel Before Important May 20 Deadline in Securities Class Action – SANA
- NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sana Biotechnology, Inc. (NASDAQ: SANA) between March 17, 2023 and November 4, 2024, inclusive (the “Class Period”), of the important May 20, 2025 lead plaintiff deadline.
- 05/19/2025
|
Sana Biotechnology, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before May 20, 2025 to Discuss Your Rights - SANA
- NEW YORK , May 19, 2025 /PRNewswire/ --The Gross Law Firm issues the following notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA). Shareholders who purchased shares of SANA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
- 05/19/2025
|
Class Action Lawsuit Alert: Levi & Korsinsky Reminds Sana Biotechnology, Inc. (SANA) Investors of May 20, 2025 Deadline
- NEW YORK, NY / ACCESS Newswire / May 19, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=149202&wire=1&utm_campaign=16 or contact Joseph E. Levi, Esq.
- 05/19/2025
|
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers - SANA
- NEW YORK CITY, NY / ACCESS Newswire / May 19, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA) and certain officers. The class action, filed in the United States District Court for the Western District of Washington, and docketed under 25-cv-00512, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against Sana and certain of its top officials.
- 05/19/2025
|
SANA Investors Have Opportunity to Lead Sana Biotechnology, Inc. Securities Fraud Lawsuit with the Schall Law Firm
- LOS ANGELES , May 19, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ: SANA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 17, 2023 and November 4, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before May 20, 2025.
- 05/19/2025
|
Join Class Action to Recover Losses from Sana Biotechnology, Inc. (SANA) - Contact Levi & Korsinsky Before May 20, 2025
- NEW YORK, NY / ACCESS Newswire / May 19, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=149135&wire=1&utm_campaign=31 or contact Joseph E. Levi, Esq.
- 05/19/2025
|
SANA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of Sana Biotechnology, Inc. to Contact the Firm Today!
- NEW YORK, NY / ACCESS Newswire / May 19, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ:SANA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period").
- 05/19/2025
|
Contact Levi & Korsinsky by May 20, 2025 to Join Class Action Against Sana Biotechnology, Inc. (SANA)
- NEW YORK, NY / ACCESS Newswire / May 18, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=149089&wire=1&utm_campaign=10 or contact Joseph E. Levi, Esq.
- 05/18/2025
|
SANA FINAL DEADLINE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Sana Biotechnology, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 20 Deadline in Securities Class Action - SANA
- NEW YORK CITY, NY / ACCESS Newswire / May 18, 2025 / WHY: New York, N.Y., May 18, 2025.
- 05/18/2025
|
Investors in Sana Biotechnology, Inc. (SANA): Protect Your Rights - Contact Levi & Korsinsky Before May 20, 2025
- NEW YORK, NY / ACCESS Newswire / May 18, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=149038&wire=1&utm_campaign=11 or contact Joseph E. Levi, Esq.
- 05/18/2025
|
Investors in Sana Biotechnology, Inc. (SANA): Protect Your Rights - Contact Levi & Korsinsky Before May 20, 2025
- NEW YORK, NY / ACCESS Newswire / May 18, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=149029&wire=1&utm_campaign=11 or contact Joseph E. Levi, Esq.
- 05/18/2025
|
SANA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Shareholders of Sana Biotechnology, Inc. to Contact the Firm Today!
- NEW YORK, NY / ACCESS Newswire / May 18, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ:SANA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period").
- 05/18/2025
|
Securities Class Action Lawsuit Filed Against Sana Biotechnology, Inc. (SANA) - Levi & Korsinsky Represents Shareholders
- NEW YORK, NY / ACCESS Newswire / May 17, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=148997&wire=1&utm_campaign=13 or contact Joseph E. Levi, Esq.
- 05/17/2025
|
SANA Deadline: Rosen Law Firm Urges Sana Biotechnology, Inc. (NASDAQ: SANA) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
- NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers and acquirers of Sana Biotechnology, Inc. (NASDAQ: SANA) securities between March 17, 2023 and November 17, 2024. Sana is a biotechnology company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that Sana Biotechnology, In.
- 05/17/2025
|
SANA Deadline: SANA Investors with Losses in Excess of $100K Have Opportunity to Lead Sana Biotechnology, Inc. Securities Fraud Lawsuit
- NEW YORK , May 17, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sana Biotechnology, Inc. (NASDAQ: SANA) between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period"), of the important May 20, 2025 lead plaintiff deadline. So what: If you purchased Sana securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 05/17/2025
|
May 20, 2025 Deadline Approaching: Join Class Action Against Sana Biotechnology, Inc. (SANA) – Contact Levi & Korsinsky
- NEW YORK, NY / ACCESS Newswire / May 16, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=148969&wire=1&utm_campaign=30 or contact Joseph E. Levi, Esq.
- 05/16/2025
|
Join Class Action to Recover Losses from Sana Biotechnology, Inc. (SANA) - Contact Levi & Korsinsky Before May 20, 2025
- NEW YORK, NY / ACCESS Newswire / May 16, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=148955&wire=1&utm_campaign=31 or contact Joseph E. Levi, Esq.
- 05/16/2025
|
May 20, 2025 Deadline: Join Class Action Lawsuit Against Sana Biotechnology, Inc. (SANA) - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESS Newswire / May 16, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=148942&wire=1&utm_campaign=6 or contact Joseph E. Levi, Esq.
- 05/16/2025
|
Sana Biotechnology, Inc. Class Action: Levi & Korsinsky Reminds Sana Biotechnology, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 20, 2025 – SANA
- NEW YORK, May 16, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit.
- 05/16/2025
|
Levi & Korsinsky Notifies Sana Biotechnology, Inc. (SANA) Investors - Lead Plaintiff Deadline on May 20, 2025
- NEW YORK, NY / ACCESS Newswire / May 16, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=148884&wire=1&utm_campaign=14 or contact Joseph E. Levi, Esq.
- 05/16/2025
|
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers - SANA
- NEW YORK, NY / ACCESS Newswire / May 16, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA) and certain officers. The class action, filed in the United States District Court for the Western District of Washington, and docketed under 25-cv-00512, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against Sana and certain of its top officials.
- 05/16/2025
|
Securities Lawsuit Alert: Sana Biotechnology, Inc. (SANA) - Contact Levi & Korsinsky Before May 20, 2025
- NEW YORK, NY / ACCESS Newswire / May 16, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=148791&wire=1&utm_campaign=3 or contact Joseph E. Levi, Esq.
- 05/16/2025
|
SANA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of Sana Biotechnology, Inc. to Contact the Firm Today!
- NEW YORK, NY / ACCESS Newswire / May 16, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ:SANA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period").
- 05/16/2025
|
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 20, 2025 in Sana Biotechnology, Inc. Lawsuit - SANA
- NEW YORK , May 16, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sana Biotechnology, Inc. investors who were adversely affected by alleged securities fraud between March 17, 2023 and November 4, 2024.
- 05/16/2025
|
Sana Biotechnology, Inc. (SANA) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of May 20, 2025 Deadline
- NEW YORK, NY / ACCESS Newswire / May 15, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=148745&wire=1&utm_campaign=1 or contact Joseph E. Levi, Esq.
- 05/15/2025
|
Levi & Korsinsky Urges Sana Biotechnology, Inc. (SANA) Shareholders to Act Before Lead Plaintiff Deadline May 20, 2025
- NEW YORK, NY / ACCESS Newswire / May 15, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=148732&wire=1&utm_campaign=18 or contact Joseph E. Levi, Esq.
- 05/15/2025
|
SANA DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Sana Biotechnology, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 20 Deadline in Securities Class Action - SANA
- NEW YORK CITY, NY / ACCESS Newswire / May 15, 2025 / WHY: New York, N.Y., May 15, 2025.
- 05/15/2025
|
Lost Money on Sana Biotechnology, Inc. (SANA)? Urged to Join Class Action Before May 20, 2025 - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESS Newswire / May 15, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=148723&wire=1&utm_campaign=22 or contact Joseph E. Levi, Esq.
- 05/15/2025
|
May 20, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against SANA
- NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA).
- 05/15/2025
|
Sana Biotechnology, Inc. (SANA) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of May 20, 2025 Deadline
- NEW YORK, NY / ACCESS Newswire / May 15, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=148701&wire=1&utm_campaign=1 or contact Joseph E. Levi, Esq.
- 05/15/2025
|
Class Action Filed Against Sana Biotechnology, Inc. (SANA) Over Securities Violations - Contact Levi & Korsinsky Today
- NEW YORK, NY / ACCESS Newswire / May 15, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=148618&wire=1&utm_campaign=29 or contact Joseph E. Levi, Esq.
- 05/15/2025
|
SANA Stockholders Have Opportunity to Lead Sana Biotechnology, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!
- NEW YORK, NY / ACCESS Newswire / May 15, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ:SANA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period").
- 05/15/2025
|
Investors in Sana Biotechnology, Inc. Should Contact The Gross Law Firm Before May 20, 2025 to Discuss Your Rights - SANA
- NEW YORK , May 15, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA). Shareholders who purchased shares of SANA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
- 05/15/2025
|
Lost Money on Sana Biotechnology, Inc. (SANA)? Join Class Action Before May 20, 2025 - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESS Newswire / May 14, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=148537&wire=1&utm_campaign=23 or contact Joseph E. Levi, Esq.
- 05/14/2025
|
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sana Biotechnology
- Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Sana To Contact Him Directly To Discuss Their Options
- 05/14/2025
|
May 20, 2025 Deadline Approaching: Join Class Action Against Sana Biotechnology, Inc. (SANA) - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESS Newswire / May 14, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=148522&wire=1&utm_campaign=30 or contact Joseph E. Levi, Esq.
- 05/14/2025
|
SANA DEADLINE: ROSEN, A LONGSTANDING FIRM, Encourages Sana Biotechnology, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 20 Deadline in Securities Class Action - SANA
- NEW YORK CITY, NY / ACCESS Newswire / May 14, 2025 / WHY: New York, N.Y., May 14, 2025.
- 05/14/2025
|
Contact Levi & Korsinsky by May 20, 2025 to Join Class Action Against Sana Biotechnology, Inc. (SANA)
- NEW YORK, NY / ACCESS Newswire / May 14, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=148486&wire=1&utm_campaign=10 or contact Joseph E. Levi, Esq.
- 05/14/2025
|
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers - SANA
- NEW YORK CITY, NY / ACCESS Newswire / May 14, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA) and certain officers. The class action, filed in the United States District Court for the Western District of Washington, and docketed under 25-cv-00512, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against Sana and certain of its top officials.
- 05/14/2025
|
Securities Fraud Class Action Filed Against Sana Biotechnology, Inc. (SANA) - Levi & Korsinsky Reminds Investors of May 20, 2025
- NEW YORK, NY / ACCESS Newswire / May 14, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=148393&wire=1&utm_campaign=27 or contact Joseph E. Levi, Esq.
- 05/14/2025
|
SANA Shareholders Have Opportunity to Lead Sana Biotechnology, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!
- NEW YORK, NY / ACCESS Newswire / May 14, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ:SANA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period").
- 05/14/2025
|
Levi & Korsinsky Reminds Sana Biotechnology, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 20, 2025 – SANA
- NEW YORK, NY / ACCESS Newswire / May 13, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=148327&wire=1 or contact Joseph E. Levi, Esq.
- 05/13/2025
|
SANA DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Sana Biotechnology, Inc. Investors to Secure Counsel Before Important May 20 Deadline in Securities Class Action - SANA
- NEW YORK CITY, NY / ACCESS Newswire / May 13, 2025 / WHY: New York, N.Y., May 13, 2025.
- 05/13/2025
|
Shareholders of Sana Biotechnology, Inc. Should Contact Levi & Korsinsky Before May 20, 2025 to Discuss Your Rights - SANA
- NEW YORK, NY / ACCESS Newswire / May 13, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=148300&wire=1 or contact Joseph E. Levi, Esq.
- 05/13/2025
|
May 20, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against SANA
- NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit.
- 05/13/2025
|
Investors in Sana Biotechnology, Inc. Should Contact Levi & Korsinsky Before May 20, 2025 to Discuss Your Rights - SANA
- NEW YORK, NY / ACCESS Newswire / May 13, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=148266&wire=1 or contact Joseph E. Levi, Esq.
- 05/13/2025
|
Sana Biotechnology, Inc. Class Action: Levi & Korsinsky Reminds Sana Biotechnology, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 20, 2025 - SANA
- NEW YORK, NY / ACCESS Newswire / May 13, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=148238&wire=1 or contact Joseph E. Levi, Esq.
- 05/13/2025
|
SANA Investors Have Opportunity to Lead Sana Biotechnology, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!
- NEW YORK, NY / ACCESS Newswire / May 13, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ:SANA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period").
- 05/13/2025
|
Class Action Filed Against Sana Biotechnology, Inc. (SANA) Seeking Recovery for Investors - Contact Levi & Korsinsky
- NEW YORK , May 13, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sana Biotechnology, Inc. investors who were adversely affected by alleged securities fraud between March 17, 2023 and November 4, 2024.
- 05/13/2025
|
Sana Biotechnology, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before May 20, 2025 to Discuss Your Rights - SANA
- NEW YORK, NY / ACCESS Newswire / May 12, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=148189&wire=1 or contact Joseph E. Levi, Esq.
- 05/12/2025
|
Sana Biotechnology to Present at the BofA Securities 2025 Healthcare Conference
- SEATTLE, May 12, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the BofA Securities 2025 Healthcare Conference at 9:20 a.m. PT on Tuesday, May 13, 2025. The presentation will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer.
- 05/12/2025
|
Class Action Filed Against Sana Biotechnology, Inc. (SANA) - May 20, 2025 Deadline to Join - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESS Newswire / May 12, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=148117&wire=1 or contact Joseph E. Levi, Esq.
- 05/12/2025
|
SANA Investors Have Opportunity to Lead Sana Biotechnology, Inc. Securities Fraud Lawsuit
- NEW YORK , May 12, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sana Biotechnology, Inc. (NASDAQ: SANA) between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period"), of the important May 20, 2025 lead plaintiff deadline. So what: If you purchased Sana securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 05/12/2025
|
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers - SANA
- NEW YORK , May 12, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ: SANA) and certain officers. The class action, filed in the United States District Court for the Western District of Washington, and docketed under 25-cv-00512, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against Sana and certain of its top officials.
- 05/12/2025
|
Sana Biotechnology, Inc. Class Action: The Gross Law Firm Reminds Sana Biotechnology, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 20, 2025 – SANA
- NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA).
- 05/12/2025
|
SANA LAWSUIT ALERT: Levi & Korsinsky Notifies Sana Biotechnology, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
- NEW YORK, NY / ACCESS Newswire / May 12, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=148095&wire=1 or contact Joseph E. Levi, Esq.
- 05/12/2025
|
ROSEN, A LEADING NATIONAL FIRM, Encourages Sana Biotechnology, Inc. Investors to Secure Counsel Before Important May 20 Deadline in Securities Class Action - SANA
- NEW YORK, NY / ACCESS Newswire / May 12, 2025 / Rosen Law Firm: WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sana Biotechnology, Inc. (NASDAQ:SANA) between March 17, 2023 and November 4, 2024, inclusive (the "Class Period"), of the important May 20, 2025 lead plaintiff deadline. SO WHAT: If you purchased Sana securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 05/12/2025
|
Class Action Filed Against Sana Biotechnology, Inc. (SANA) Seeking Recovery for Investors - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESS Newswire / May 12, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=148081&wire=1 or contact Joseph E. Levi, Esq.
- 05/12/2025
|
SANA Investors Have Opportunity to Lead Sana Biotechnology, Inc. Securities Fraud Lawsuit with the Schall Law Firm
- LOS ANGELES , May 12, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ: SANA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 17, 2023 and November 4, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before May 20, 2025.
- 05/12/2025
|
Sana Biotechnology, Inc. Class Action: Levi & Korsinsky Reminds Sana Biotechnology, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 20, 2025 - SANA
- NEW YORK, NY / ACCESS Newswire / May 12, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=148006&wire=1 or contact Joseph E. Levi, Esq.
- 05/12/2025
|
SANA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sana Biotechnology, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESS Newswire / May 12, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ:SANA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period").
- 05/12/2025
|
Sana Biotechnology, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before May 20, 2025 to Discuss Your Rights - SANA
- NEW YORK , May 12, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA). Shareholders who purchased shares of SANA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
- 05/12/2025
|
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 20, 2025 in Sana Biotechnology, Inc. Lawsuit - SANA
- NEW YORK, NY / ACCESS Newswire / May 11, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=147976&wire=1 or contact Joseph E. Levi, Esq.
- 05/11/2025
|
Class Action Filed Against Sana Biotechnology, Inc. (SANA) Seeking Recovery for Investors - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESS Newswire / May 11, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=147949&wire=1 or contact Joseph E. Levi, Esq.
- 05/11/2025
|
Contact Levi & Korsinsky by May 20, 2025 Deadline to Join Class Action Against Sana Biotechnology, Inc.(SANA)
- NEW YORK, NY / ACCESS Newswire / May 11, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=147930&wire=1 or contact Joseph E. Levi, Esq.
- 05/11/2025
|
Faruqi & Faruqi Reminds Sana Biotechnology Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 20, 2025 - SANA
- Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Sana To Contact Him Directly To Discuss Their Options
- 05/11/2025
|
Sana Biotechnology, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before May 20, 2025 to Discuss Your Rights - SANA
- NEW YORK, NY / ACCESS Newswire / May 11, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=147908&wire=1 or contact Joseph E. Levi, Esq.
- 05/11/2025
|
SANA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sana Biotechnology, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESS Newswire / May 11, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ:SANA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period").
- 05/11/2025
|
Shareholders of Sana Biotechnology, Inc. Should Contact Levi & Korsinsky Before May 20, 2025 to Discuss Your Rights - SANA
- NEW YORK, NY / ACCESS Newswire / May 10, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=147840&wire=1 or contact Joseph E. Levi, Esq.
- 05/10/2025
|
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers SANA
- NEW YORK, NY / ACCESS Newswire / May 10, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA) and certain officers. The class action, filed in the United States District Court for the Western District of Washington, and docketed under 25-cv-00512, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against Sana and certain of its top officials.
- 05/10/2025
|
SANA LAWSUIT ALERT: Levi & Korsinsky Notifies Sana Biotechnology, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
- NEW YORK, NY / ACCESS Newswire / May 9, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=147835&wire=1 or contact Joseph E. Levi, Esq.
- 05/09/2025
|
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 20, 2025 in Sana Biotechnology, Inc. Lawsuit – SANA
- NEW YORK, NY / ACCESS Newswire / May 9, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=147823&wire=1 or contact Joseph E. Levi, Esq.
- 05/09/2025
|
SANA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sana Biotechnology, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
- NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sana Biotechnology, Inc. (“Sana” or “the Company”) (NASDAQ: SANA) and certain of its officers.
- 05/09/2025
|
Investors Who Lost Money on Sana Biotechnology, Inc. (SANA) Should Contact Levi & Korsinsky about Pending Class Action - SANA
- NEW YORK, NY / ACCESS Newswire / May 9, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=147706&wire=1 or contact Joseph E. Levi, Esq.
- 05/09/2025
|
Class Action Filed Against Sana Biotechnology, Inc. (SANA) - May 20, 2025 Deadline to Join - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESS Newswire / May 9, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=147687&wire=1 or contact Joseph E. Levi, Esq.
- 05/09/2025
|
SANA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sana Biotechnology, Inc. Investors Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESS Newswire / May 9, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ:SANA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period").
- 05/09/2025
|
Levi & Korsinsky Notifies Shareholders of Sana Biotechnology, Inc.(SANA) of a Class Action Lawsuit and an Upcoming Deadline
- NEW YORK , May 9, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sana Biotechnology, Inc. investors who were adversely affected by alleged securities fraud between March 17, 2023 and November 4, 2024.
- 05/09/2025
|
Shareholders that lost money on Sana Biotechnology, Inc.(SANA) should contact Levi & Korsinsky about pending Class Action - SANA
- NEW YORK, NY / ACCESS Newswire / May 8, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=147658&wire=1 or contact Joseph E. Levi, Esq.
- 05/08/2025
|
SANA SHAREHOLDER ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Sana Biotechnology, Inc. Investors to Secure Counsel Before Important May 20 Deadline in Securities Class Action - SANA
- NEW YORK CITY, NY / ACCESS Newswire / May 8, 2025 / WHY: New York, N.Y., May 8, 2025.
- 05/08/2025
|
Levi & Korsinsky Reminds Sana Biotechnology, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 20, 2025 - SANA
- NEW YORK, NY / ACCESS Newswire / May 8, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=147625&wire=1 or contact Joseph E. Levi, Esq.
- 05/08/2025
|
Shareholders That Lost Money on Sana Biotechnology, Inc. (SANA) Should Contact Levi & Korsinsky About Pending Class Action - SANA
- NEW YORK, NY / ACCESS Newswire / May 8, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=147610&wire=1 or contact Joseph E. Levi, Esq.
- 05/08/2025
|
SANA LAWSUIT ALERT: Levi & Korsinsky Notifies Sana Biotechnology, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
- NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit.
- 05/08/2025
|
Lost Money on Sana Biotechnology, Inc.(SANA)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESS Newswire / May 8, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=147530&wire=1 or contact Joseph E. Levi, Esq.
- 05/08/2025
|
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers - SANA
- NEW YORK CITY, NY / ACCESS Newswire / May 8, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA) and certain officers. The class action, filed in the United States District Court for the Western District of Washington, and docketed under 25-cv-00512, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against Sana and certain of its top officials.
- 05/08/2025
|
Levi & Korsinsky Notifies Sana Biotechnology, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - SANA
- NEW YORK, NY / ACCESS Newswire / May 8, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=147493&wire=1 or contact Joseph E. Levi, Esq.
- 05/08/2025
|
SANA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sana Biotechnology, Inc. Investors Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESS Newswire / May 8, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ:SANA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period").
- 05/08/2025
|
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 20, 2025 in Sana Biotechnology, Inc. Lawsuit - SANA
- NEW YORK , May 8, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA). Shareholders who purchased shares of SANA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
- 05/08/2025
|
Sana Biotechnology, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before May 20, 2025 to Discuss Your Rights - SANA
- NEW YORK, NY / ACCESS Newswire / May 7, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=147445&wire=1 or contact Joseph E. Levi, Esq.
- 05/07/2025
|
SANA Investors Have Opportunity to Lead Sana Biotechnology, Inc. Securities Fraud Lawsuit
- NEW YORK , May 7, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sana Biotechnology, Inc. (NASDAQ: SANA) between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period"), of the important May 20, 2025 lead plaintiff deadline. So what: If you purchased Sana securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 05/07/2025
|
Investors in Sana Biotechnology, Inc. Should Contact Levi & Korsinsky Before May 20, 2025 to Discuss Your Rights - SANA
- NEW YORK, NY / ACCESS Newswire / May 7, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=147403&wire=1 or contact Joseph E. Levi, Esq.
- 05/07/2025
|
Lost Money on Sana Biotechnology, Inc. (SANA)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESS Newswire / May 7, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=147388&wire=1 or contact Joseph E. Levi, Esq.
- 05/07/2025
|
Sana Biotechnology, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – SANA
- NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA).
- 05/07/2025
|
SANA Investors Have Opportunity to Lead Sana Biotechnology, Inc. Securities Fraud Lawsuit with the Schall Law Firm
- LOS ANGELES , May 7, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ: SANA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 17, 2023 and November 4, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before May 20, 2025.
- 05/07/2025
|
Levi & Korsinsky Notifies Sana Biotechnology, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - SANA
- NEW YORK, NY / ACCESS Newswire / May 7, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=147371&wire=1 or contact Joseph E. Levi, Esq.
- 05/07/2025
|
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sana Biotechnology
- Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Sana To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Sana between March 17, 2023 and November 4, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , May 7, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ: SANA) and reminds investors of the May 20, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
- 05/07/2025
|
Sana Biotechnology, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before May 20, 2025 to Discuss Your Rights - SANA
- NEW YORK, NY / ACCESS Newswire / May 7, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=147284&wire=1 or contact Joseph E. Levi, Esq.
- 05/07/2025
|
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers - SANA
- NEW YORK CITY, NY / ACCESS Newswire / May 7, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA) and certain officers. The class action, filed in the United States District Court for the Western District of Washington, and docketed under 25-cv-00512, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against Sana and certain of its top officials.
- 05/07/2025
|
Shareholders that lost money on Sana Biotechnology, Inc. (SANA) should contact Levi & Korsinsky about pending Class Action - SANA
- NEW YORK, NY / ACCESS Newswire / May 7, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=147232&wire=1 or contact Joseph E. Levi, Esq.
- 05/07/2025
|
SANA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sana Biotechnology, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESS Newswire / May 7, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ:SANA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period").
- 05/07/2025
|
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers - SANA
- NEW YORK , May 6, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ: SANA) and certain officers. The class action, filed in the United States District Court for the Western District of Washington, and docketed under 25-cv-00512, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against Sana and certain of its top officials.
- 05/06/2025
|
Sana Biotechnology, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before May 20, 2025 to Discuss Your Rights - SANA
- NEW YORK, NY / ACCESS Newswire / May 6, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=147089&wire=1 or contact Joseph E. Levi, Esq.
- 05/06/2025
|
SANA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sana Biotechnology, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESS Newswire / May 6, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ:SANA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period").
- 05/06/2025
|
Shareholders that lost money on Sana Biotechnology, Inc.(SANA) should contact Levi & Korsinsky about pending Class Action - SANA
- NEW YORK , May 6, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sana Biotechnology, Inc. investors who were adversely affected by alleged securities fraud between March 17, 2023 and November 4, 2024.
- 05/06/2025
|
Sana Biotechnology, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before May 20, 2025 to Discuss Your Rights - SANA
- NEW YORK, NY / ACCESS Newswire / May 5, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=147075&wire=1 or contact Joseph E. Levi, Esq.
- 05/05/2025
|
Shareholders That Lost Money on Sana Biotechnology, Inc. (SANA) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
- NEW YORK, NY / ACCESS Newswire / May 5, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=147041&wire=1 or contact Joseph E. Levi, Esq.
- 05/05/2025
|
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 20, 2025 in Sana Biotechnology, Inc. Lawsuit – SANA
- NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit.
- 05/05/2025
|
Shareholders that lost money on Sana Biotechnology, Inc. (SANA) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
- NEW YORK, NY / ACCESS Newswire / May 5, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=146975&wire=1 or contact Joseph E. Levi, Esq.
- 05/05/2025
|
Investors in Sana Biotechnology, Inc. Should Contact Levi & Korsinsky Before May 20, 2025 to Discuss Your Rights - SANA
- NEW YORK, NY / ACCESS Newswire / May 5, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=146963&wire=1 or contact Joseph E. Levi, Esq.
- 05/05/2025
|
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers – SANA
- NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Sana Biotechnology, Inc. (“Sana” or the “Company”) (NASDAQ: SANA) and certain officers. The class action, filed in the United States District Court for the Western District of Washington, and docketed under 25-cv-00512, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, against Sana and certain of its top officials.
- 05/05/2025
|
Shareholders that lost money on Sana Biotechnology, Inc. (SANA) should contact Levi & Korsinsky about pending Class Action - SANA
- NEW YORK, NY / ACCESS Newswire / May 5, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=146907&wire=1 or contact Joseph E. Levi, Esq.
- 05/05/2025
|
SANA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sana Biotechnology, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESS Newswire / May 5, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ:SANA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period").
- 05/05/2025
|
Shareholders that lost money on Sana Biotechnology, Inc.(SANA) Urged to Join Class Action - Contact The Gross Law Firm to Learn More
- NEW YORK , May 5, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA). Shareholders who purchased shares of SANA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
- 05/05/2025
|
Lost Money on Sana Biotechnology, Inc. (SANA)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESS Newswire / May 5, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=146880&wire=1 or contact Joseph E. Levi, Esq.
- 05/05/2025
|
SANA Investors Have Opportunity to Lead Sana Biotechnology, Inc. Securities Fraud Lawsuit
- NEW YORK , May 5, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sana Biotechnology, Inc. (NASDAQ: SANA) between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period"), of the important May 20, 2025 lead plaintiff deadline. So what: If you purchased Sana securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 05/05/2025
|
Shareholders that lost money on Sana Biotechnology, Inc.(SANA) should contact Levi & Korsinsky about pending Class Action - SANA
- NEW YORK, NY / ACCESS Newswire / May 4, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=146878&wire=1 or contact Joseph E. Levi, Esq.
- 05/04/2025
|
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Sana Biotechnology, Inc.(SANA) Shareholders
- NEW YORK, NY / ACCESS Newswire / May 4, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=146876&wire=1 or contact Joseph E. Levi, Esq.
- 05/04/2025
|
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Sana Biotechnology, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SANA
- NEW YORK, NY / ACCESS Newswire / May 4, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sana Biotechnology, Inc. (NASDAQ:SANA) between March 17, 2023 and November 4, 2024, inclusive (the "Class Period"), of the important May 20, 2025 lead plaintiff deadline. SO WHAT: If you purchased Sana securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 05/04/2025
|
Investors in Sana Biotechnology, Inc. Should Contact Levi & Korsinsky Before May 20, 2025 to Discuss Your Rights - SANA
- NEW YORK, NY / ACCESS Newswire / May 4, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=146856&wire=1 or contact Joseph E. Levi, Esq.
- 05/04/2025
|
SANA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sana Biotechnology, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
- NEW YORK, May 04, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sana Biotechnology, Inc. (“Sana” or “the Company”) (NASDAQ: SANA) and certain of its officers.
- 05/04/2025
|
Lost Money on Sana Biotechnology, Inc.(SANA)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESS Newswire / May 4, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=146786&wire=1 or contact Joseph E. Levi, Esq.
- 05/04/2025
|
SANA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sana Biotechnology, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESS Newswire / May 4, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ:SANA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period").
- 05/04/2025
|
Lost Money on Sana Biotechnology, Inc.(SANA)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESS Newswire / May 3, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=146764&wire=1 or contact Joseph E. Levi, Esq.
- 05/03/2025
|
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers - SANA
- NEW YORK CITY, NY / ACCESS Newswire / May 3, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA) and certain officers. The class action, filed in the United States District Court for the Western District of Washington, and docketed under 25-cv-00512, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against Sana and certain of its top officials.
- 05/03/2025
|
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sana Biotechnology
- NEW YORK, NY / ACCESS Newswire / May 3, 2025 / Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Sana To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Sana between March 17, 2023 and November 4, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA) and reminds investors of the May 20, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
- 05/03/2025
|
May 20, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against SANA
- NEW YORK, NY / ACCESS Newswire / May 2, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=146717&wire=1 or contact Joseph E. Levi, Esq.
- 05/02/2025
|
SANA Investor Alert: SANA Stockholders with Large Losses are Encouraged to Contact Robbins LLP for Information on Leading the Class Action Against Sana Biotechnology, Inc.
- SAN DIEGO, CA / ACCESS Newswire / May 2, 2025 / Robbins LLP reminds stockholders that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Sana Biotechnology, Inc. (NASDAQ:SANA) securities between March 17, 2023 and November 4, 2024. Sana is a biotechnology company that develops ex vivo and in vivo cell engineering programs to purportedly revolutionize treatment across a broad array of therapeutic areas with unmet treatment needs, including, inter alia, oncology, diabetes, central nervous system ("CNS") disorders, and B-cell-mediated autoimmune diseases.
- 05/02/2025
|
Shareholders that lost money on Sana Biotechnology, Inc. (SANA) should contact Levi & Korsinsky about pending Class Action - SANA
- NEW YORK, May 02, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit.
- 05/02/2025
|
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 20, 2025 in Sana Biotechnology, Inc. Lawsuit - SANA
- NEW YORK, NY / ACCESS Newswire / May 2, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=146654&wire=1 or contact Joseph E. Levi, Esq.
- 05/02/2025
|
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers - SANA
- NEW YORK CITY, NY / ACCESS Newswire / May 2, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA) and certain officers. The class action, filed in the United States District Court for the Western District of Washington, and docketed under 25-cv-00512, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against Sana and certain of its top officials.
- 05/02/2025
|
Sana Biotechnology, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before May 20, 2025 to Discuss Your Rights - SANA
- NEW YORK, NY / ACCESS Newswire / May 2, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=146560&wire=1 or contact Joseph E. Levi, Esq.
- 05/02/2025
|
SANA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sana Biotechnology, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESS Newswire / May 2, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ:SANA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period").
- 05/02/2025
|
Sana Biotechnology, Inc. Class Action: Levi & Korsinsky Reminds Sana Biotechnology, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 20, 2025 - SANA
- NEW YORK , May 2, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sana Biotechnology, Inc. investors who were adversely affected by alleged securities fraud between March 17, 2023 and November 4, 2024.
- 05/02/2025
|
SANA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sana Biotechnology, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
- NEW YORK, April 27, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sana Biotechnology, Inc. (“Sana” or “the Company”) (NASDAQ: SANA) and certain of its officers.
- 04/27/2025
|
ROSEN, A GLOBAL INVESTOR RIGHTS LAW FIRM, Encourages Sana Biotechnology, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SANA
- NEW YORK, April 27, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sana Biotechnology, Inc. (NASDAQ: SANA) between March 17, 2023 and November 4, 2024, inclusive (the “Class Period”), of the important May 20, 2025 lead plaintiff deadline.
- 04/27/2025
|
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sana Biotechnology
- Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Sana To Contact Him Directly To Discuss Their Options
- 04/26/2025
|
Lost Money on Sana Biotechnology, Inc. (SANA)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESS Newswire / April 25, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=145154&wire=1 or contact Joseph E. Levi, Esq.
- 04/25/2025
|
SANA Investors Have the Opportunity to Lead the Sana Biotechnology Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
- Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Sana To Contact Him Directly To Discuss Their Options NEW YORK CITY, NY / ACCESS Newswire / April 25, 2025 / If you suffered losses exceeding $50,000 in Sana between March 17, 2023 and November 4, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA) and reminds investors of the May 20, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
- 04/25/2025
|
Levi & Korsinsky Notifies Sana Biotechnology, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - SANA
- NEW YORK, NY / ACCESS Newswire / April 25, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=145101&wire=1 or contact Joseph E. Levi, Esq.
- 04/25/2025
|
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers – SANA
- NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Sana Biotechnology, Inc. (“Sana” or the “Company”) (NASDAQ: SANA) and certain officers. The class action, filed in the United States District Court for the Western District of Washington, and docketed under 25-cv-00512, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, against Sana and certain of its top officials.
- 04/25/2025
|
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Sana Biotechnology, Inc. (SANA) Shareholders
- NEW YORK, NY / ACCESS Newswire / April 25, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=145018&wire=1 or contact Joseph E. Levi, Esq.
- 04/25/2025
|
SANA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sana Biotechnology, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESS Newswire / April 25, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ:SANA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period").
- 04/25/2025
|
Contact Levi & Korsinsky by May 20, 2025 Deadline to Join Class Action Against Sana Biotechnology, Inc.(SANA)
- NEW YORK , April 25, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sana Biotechnology, Inc. investors who were adversely affected by alleged securities fraud between March 17, 2023 and November 4, 2024.
- 04/25/2025
|
SANA LAWSUIT ALERT: Levi & Korsinsky Notifies Sana Biotechnology, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
- NEW YORK, NY / ACCESS Newswire / April 25, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=145000&wire=1 or contact Joseph E. Levi, Esq.
- 04/25/2025
|
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Sana Biotechnology, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SANA
- NEW YORK CITY, NY / ACCESS Newswire / April 24, 2025 / WHY: New York, N.Y., April 24, 2025.
- 04/24/2025
|
Contact Levi & Korsinsky by May 20, 2025 Deadline to Join Class Action Against Sana Biotechnology, Inc. (SANA)
- NEW YORK, NY / ACCESS Newswire / April 24, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=144947&wire=1 or contact Joseph E. Levi, Esq.
- 04/24/2025
|
Levi & Korsinsky Reminds Sana Biotechnology, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 20, 2025 – SANA
- NEW YORK, April 24, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit.
- 04/24/2025
|
Sana Biotechnology, Inc. Class Action: Levi & Korsinsky Reminds Sana Biotechnology, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 20, 2025 - SANA
- NEW YORK, NY / ACCESS Newswire / April 24, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=144919&wire=1 or contact Joseph E. Levi, Esq.
- 04/24/2025
|
SANA Investors Have Opportunity to Lead Sana Biotechnology, Inc. Securities Fraud Lawsuit with the Schall Law Firm
- LOS ANGELES , April 24, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ: SANA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 17, 2023 and November 4, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before May 20, 2025.
- 04/24/2025
|
Levi & Korsinsky Notifies Shareholders of Sana Biotechnology, Inc. (SANA) of a Class Action Lawsuit and an Upcoming Deadline
- NEW YORK, NY / ACCESS Newswire / April 24, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=144862&wire=1 or contact Joseph E. Levi, Esq.
- 04/24/2025
|
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers - SANA
- NEW YORK CITY, NY / ACCESS Newswire / April 24, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA) and certain officers. The class action, filed in the United States District Court for the Western District of Washington, and docketed under 25-cv-00512, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against Sana and certain of its top officials.
- 04/24/2025
|
Class Action Filed Against Sana Biotechnology, Inc. (SANA) Seeking Recovery for Investors - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESS Newswire / April 24, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=144837&wire=1 or contact Joseph E. Levi, Esq.
- 04/24/2025
|
SANA Shareholders Have Opportunity to Lead Sana Biotechnology, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!
- NEW YORK, NY / ACCESS Newswire / April 24, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ:SANA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period").
- 04/24/2025
|
Shareholders that lost money on Sana Biotechnology, Inc.(SANA) should contact The Gross Law Firm about pending Class Action - SANA
- NEW YORK , April 24, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA). Shareholders who purchased shares of SANA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
- 04/24/2025
|
Levi & Korsinsky Notifies Sana Biotechnology, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - SANA
- NEW YORK, NY / ACCESS Newswire / April 23, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=144789&wire=1 or contact Joseph E. Levi, Esq.
- 04/23/2025
|
Levi & Korsinsky Notifies Shareholders of Sana Biotechnology, Inc. (SANA) of a Class Action Lawsuit and an Upcoming Deadline
- NEW YORK, NY / ACCESS Newswire / April 21, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=144325&wire=1 or contact Joseph E. Levi, Esq.
- 04/21/2025
|
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Sana Biotechnology, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SANA
- NEW YORK CITY, NY / ACCESS Newswire / April 21, 2025 / WHY: New York, N.Y., April 21, 2025.
- 04/21/2025
|
Sana Biotechnology, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before May 20, 2025 to Discuss Your Rights - SANA
- NEW YORK, NY / ACCESS Newswire / April 21, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=144307&wire=1 or contact Joseph E. Levi, Esq.
- 04/21/2025
|
ROSEN, A RANKED AND LEADING FIRM, Encourages Sana Biotechnology, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SANA
- NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sana Biotechnology, Inc. (NASDAQ: SANA) between March 17, 2023 and November 4, 2024, inclusive (the “Class Period”), of the important May 20, 2025 lead plaintiff deadline.
- 04/21/2025
|
Sana Biotechnology, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before May 20, 2025 to Discuss Your Rights – SANA
- NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit.
- 04/21/2025
|
Shareholders of Sana Biotechnology, Inc. Should Contact Levi & Korsinsky Before May 20, 2025 to Discuss Your Rights - SANA
- NEW YORK, NY / ACCESS Newswire / April 21, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=144265&wire=1 or contact Joseph E. Levi, Esq.
- 04/21/2025
|
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers – SANA
- NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Sana Biotechnology, Inc. (“Sana” or the “Company”) (NASDAQ: SANA) and certain officers. The class action, filed in the United States District Court for the Western District of Washington, and docketed under 25-cv-00512, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, against Sana and certain of its top officials.
- 04/21/2025
|
Sana Biotechnology, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - SANA
- NEW YORK, NY / ACCESS Newswire / April 21, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=144196&wire=1 or contact Joseph E. Levi, Esq.
- 04/21/2025
|
SANA Investors Have Opportunity to Lead Sana Biotechnology, Inc. Securities Fraud Lawsuit
- NEW YORK , April 21, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sana Biotechnology, Inc. (NASDAQ: SANA) between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period"), of the important May 20, 2025 lead plaintiff deadline. So what: If you purchased Sana securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 04/21/2025
|
SANA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sana Biotechnology, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESS Newswire / April 21, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ:SANA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period").
- 04/21/2025
|
The Gross Law Firm Reminds Sana Biotechnology, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 20, 2025 - SANA
- NEW YORK , April 21, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA). Shareholders who purchased shares of SANA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
- 04/21/2025
|
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 20, 2025 in Sana Biotechnology, Inc. Lawsuit - SANA
- NEW YORK, NY / ACCESS Newswire / April 20, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=144152&wire=1 or contact Joseph E. Levi, Esq.
- 04/20/2025
|
Sana Biotechnology, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before May 20, 2025 to Discuss Your Rights - SANA
- NEW YORK, NY / ACCESS Newswire / April 20, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=144127&wire=1 or contact Joseph E. Levi, Esq.
- 04/20/2025
|
SANA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sana Biotechnology, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
- NEW YORK, April 20, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sana Biotechnology, Inc. (“Sana” or “the Company”) (NASDAQ: SANA) and certain of its officers.
- 04/20/2025
|
May 20, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against SANA
- NEW YORK, NY / ACCESS Newswire / April 20, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=144096&wire=1 or contact Joseph E. Levi, Esq.
- 04/20/2025
|
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers - SANA
- NEW YORK CITY, NY / ACCESS Newswire / April 20, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA) and certain officers. The class action, filed in the United States District Court for the Western District of Washington, and docketed under 25-cv-00512, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against Sana and certain of its top officials.
- 04/20/2025
|
Lost Money on Sana Biotechnology, Inc.(SANA)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESS Newswire / April 20, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=144067&wire=1 or contact Joseph E. Levi, Esq.
- 04/20/2025
|
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 20, 2025 in Sana Biotechnology, Inc. Lawsuit - SANA
- NEW YORK, NY / ACCESS Newswire / April 20, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=144030&wire=1 or contact Joseph E. Levi, Esq.
- 04/20/2025
|
SANA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sana Biotechnology, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESS Newswire / April 20, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ:SANA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period").
- 04/20/2025
|
Class Action Filed Against Sana Biotechnology, Inc. (SANA) - May 20, 2025 Deadline to Join - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESS Newswire / April 19, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=144020&wire=1 or contact Joseph E. Levi, Esq.
- 04/19/2025
|
Sana Biotechnology, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before May 20, 2025 to Discuss Your Rights - SANA
- NEW YORK, NY / ACCESS Newswire / April 19, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=144008&wire=1 or contact Joseph E. Levi, Esq.
- 04/19/2025
|
ROSEN, A TOP RANKED LAW FIRM, Encourages Sana Biotechnology, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SANA
- NEW YORK, NY / ACCESS Newswire / April 19, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sana Biotechnology, Inc. (NASDAQ:SANA) between March 17, 2023 and November 4, 2024, inclusive (the "Class Period"), of the important May 20, 2025 lead plaintiff deadline. SO WHAT: If you purchased Sana securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 04/19/2025
|
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sana Biotechnology
- Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Sana To Contact Him Directly To Discuss Their Options NEW YORK, NY / ACCESS Newswire / April 19, 2025 / If you suffered losses exceeding $50,000 in Sana between March 17, 2023 and November 4, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA) and reminds investors of the May 20, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
- 04/19/2025
|
Bitfarms Ltd. Announcement: If You Have Suffered Losses in Bitfarms Ltd.
- NEW YORK, April 18, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Bitfarms Ltd. (NASDAQ: BITF) resulting from allegations that Bitfarms may have issued materially misleading business information to the investing public.
- 04/18/2025
|
Lost Money on Sana Biotechnology, Inc. (SANA)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESS Newswire / April 18, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=143926&wire=1 or contact Joseph E. Levi, Esq.
- 04/18/2025
|
Lost Money on Sana Biotechnology, Inc.(SANA)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky
- NEW YORK, April 18, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit.
- 04/18/2025
|
Shareholders of Sana Biotechnology, Inc. Should Contact Levi & Korsinsky Before May 20, 2025 to Discuss Your Rights - SANA
- NEW YORK, NY / ACCESS Newswire / April 18, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=143806&wire=1 or contact Joseph E. Levi, Esq.
- 04/18/2025
|
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers - SANA
- NEW YORK CITY, NY / ACCESS Newswire / April 18, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA) and certain officers. The class action, filed in the United States District Court for the Western District of Washington, and docketed under 25-cv-00512, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against Sana and certain of its top officials.
- 04/18/2025
|
Levi & Korsinsky Reminds Sana Biotechnology, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 20, 2025 - SANA
- NEW YORK, NY / ACCESS Newswire / April 18, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=143781&wire=1 or contact Joseph E. Levi, Esq.
- 04/18/2025
|
SANA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sana Biotechnology, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESS Newswire / April 18, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ:SANA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period").
- 04/18/2025
|
Levi & Korsinsky Notifies Shareholders of Sana Biotechnology, Inc.(SANA) of a Class Action Lawsuit and an Upcoming Deadline
- NEW YORK , April 18, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sana Biotechnology, Inc. investors who were adversely affected by alleged securities fraud between March 17, 2023 and November 4, 2024.
- 04/18/2025
|
Levi & Korsinsky Reminds Sana Biotechnology, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 20, 2025 - SANA
- NEW YORK, NY / ACCESS Newswire / April 17, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=143752&wire=1 or contact Joseph E. Levi, Esq.
- 04/17/2025
|
Sana Biotechnology, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - SANA
- NEW YORK, NY / ACCESS Newswire / April 17, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=143728&wire=1 or contact Joseph E. Levi, Esq.
- 04/17/2025
|
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Sana Biotechnology, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SANA
- NEW YORK CITY, NY / ACCESS Newswire / April 17, 2025 / WHY: New York, N.Y., April 17, 2025.
- 04/17/2025
|
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 20, 2025 in Sana Biotechnology, Inc. Lawsuit - SANA
- NEW YORK, NY / ACCESS Newswire / April 17, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=143706&wire=1 or contact Joseph E. Levi, Esq.
- 04/17/2025
|
Sana Biotechnology, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before May 20, 2025 to Discuss Your Rights - SANA
- NEW YORK, NY / ACCESS Newswire / April 17, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=143677&wire=1 or contact Joseph E. Levi, Esq.
- 04/17/2025
|
Class Action Filed Against Sana Biotechnology, Inc. (SANA) - May 20, 2025 Deadline to Join - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESS Newswire / April 17, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=143562&wire=1 or contact Joseph E. Levi, Esq.
- 04/17/2025
|
Sana Biotechnology, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before May 20, 2025 to Discuss Your Rights – SANA
- NEW YORK, NY / ACCESS Newswire / April 17, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=143534&wire=1 or contact Joseph E. Levi, Esq.
- 04/17/2025
|
SANA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of Sana Biotechnology, Inc. to Contact the Firm Today!
- NEW YORK, NY / ACCESS Newswire / April 17, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ:SANA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period").
- 04/17/2025
|
The Gross Law Firm Reminds Sana Biotechnology, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 20, 2025 - SANA
- NEW YORK , April 17, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA). Shareholders who purchased shares of SANA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
- 04/17/2025
|
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 20, 2025 in Sana Biotechnology, Inc. Lawsuit - SANA
- NEW YORK CITY, NY / ACCESS Newswire / April 16, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=143524&wire=1 or contact Joseph E. Levi, Esq.
- 04/16/2025
|
SANA LAWSUIT ALERT: Levi & Korsinsky Notifies Sana Biotechnology, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
- NEW YORK, NY / ACCESS Newswire / April 16, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=143510&wire=1 or contact Joseph E. Levi, Esq.
- 04/16/2025
|
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Sana Biotechnology, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SANA
- NEW YORK CITY, NY / ACCESS Newswire / April 16, 2025 / WHY: New York, N.Y., April 16, 2025.
- 04/16/2025
|
Sana Biotechnology, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - SANA
- NEW YORK, NY / ACCESS Newswire / April 16, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=143398&wire=1 or contact Joseph E. Levi, Esq.
- 04/16/2025
|
Sana Biotechnology, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. May 20, 2025 Deadline to file Lead Plaintiff Motion.
- Investors can contact the law firm at no cost to learn more about recovering their losses
- 04/16/2025
|
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers - SANA
- NEW YORK, NY / ACCESS Newswire / April 16, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA) and certain officers. The class action, filed in the United States District Court for the Western District of Washington, and docketed under 25-cv-00512, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against Sana and certain of its top officials.
- 04/16/2025
|
Investors in Sana Biotechnology, Inc. Should Contact Levi & Korsinsky Before May 20, 2025 to Discuss Your Rights - SANA
- NEW YORK, NY / ACCESS Newswire / April 16, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=143388&wire=1 or contact Joseph E. Levi, Esq.
- 04/16/2025
|
SANA Investors Have the Opportunity to Lead the Sana Biotechnology Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
- Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Sana To Contact Him Directly To Discuss Their Options
- 04/16/2025
|
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 20, 2025 in Sana Biotechnology, Inc. Lawsuit - SANA
- NEW YORK, NY / ACCESS Newswire / April 16, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=143297&wire=1 or contact Joseph E. Levi, Esq.
- 04/16/2025
|
SANA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Shareholders of Sana Biotechnology, Inc. to Contact the Firm Today!
- NEW YORK, NY / ACCESS Newswire / April 16, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ:SANA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period").
- 04/16/2025
|
Levi & Korsinsky Notifies Shareholders of Sana Biotechnology, Inc. (SANA) of a Class Action Lawsuit and an Upcoming Deadline
- NEW YORK, NY / ACCESS Newswire / April 15, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=143280&wire=1 or contact Joseph E. Levi, Esq.
- 04/15/2025
|
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 20, 2025 in Sana Biotechnology, Inc. Lawsuit - SANA
- NEW YORK, NY / ACCESS Newswire / April 15, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=143233&wire=1 or contact Joseph E. Levi, Esq.
- 04/15/2025
|
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Sana Biotechnology, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SANA
- NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sana Biotechnology, Inc. (NASDAQ: SANA) between March 17, 2023 and November 4, 2024, inclusive (the “Class Period”), of the important May 20, 2025 lead plaintiff deadline.
- 04/15/2025
|
May 20, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against SANA
- NEW YORK, NY / ACCESS Newswire / April 15, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=143143&wire=1 or contact Joseph E. Levi, Esq.
- 04/15/2025
|
Levi & Korsinsky Reminds Sana Biotechnology, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 20, 2025 - SANA
- NEW YORK, NY / ACCESS Newswire / April 15, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=143123&wire=1 or contact Joseph E. Levi, Esq.
- 04/15/2025
|
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers - SANA
- NEW YORK CITY, NY / ACCESS Newswire / April 15, 2025 / NEW YORK, April 14, 2025 (ACCESSWIRE) Pomerantz LLP announces that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA) and certain officers. The class action, filed in the United States District Court for the Western District of Washington, and docketed under 25-cv-00512, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against Sana and certain of its top officials.
- 04/15/2025
|
Sana Biotechnology, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before May 20, 2025 to Discuss Your Rights - SANA
- NEW YORK, NY / ACCESS Newswire / April 15, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=143111&wire=1 or contact Joseph E. Levi, Esq.
- 04/15/2025
|
SANA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of Sana Biotechnology, Inc. to Contact the Firm Today!
- NEW YORK, NY / ACCESS Newswire / April 15, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ:SANA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period").
- 04/15/2025
|
Class Action Filed Against Sana Biotechnology, Inc. (SANA) - May 20, 2025 Deadline to Join - Contact Levi & Korsinsky
- NEW YORK CITY, NY / ACCESS Newswire / April 14, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=143065&wire=1 or contact Joseph E. Levi, Esq.
- 04/14/2025
|
SANA LAWSUIT ALERT: Levi & Korsinsky Notifies Sana Biotechnology, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
- NEW YORK, NY / ACCESS Newswire / April 14, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=143058&wire=1 or contact Joseph E. Levi, Esq.
- 04/14/2025
|
ROSEN, LEADING INVESTOR COUNSEL, Encourages Sana Biotechnology, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SANA
- NEW YORK, NY / ACCESS Newswire / April 14, 2025 / The Rosen Law Firm, P.A. WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sana Biotechnology, Inc. (NASDAQ:SANA) between March 17, 2023 and November 4, 2024, inclusive (the "Class Period"), of the important May 20, 2025 lead plaintiff deadline.
- 04/14/2025
|
Shareholders That Lost Money on Sana Biotechnology, Inc. (SANA) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
- NEW YORK, NY / ACCESS Newswire / April 14, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=142995&wire=1 or contact Joseph E. Levi, Esq.
- 04/14/2025
|
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers - SANA
- NEW YORK , April 14, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ: SANA) and certain officers. The class action, filed in the United States District Court for the Western District of Washington, and docketed under 25-cv-00512, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against Sana and certain of its top officials.
- 04/14/2025
|
Levi & Korsinsky Notifies Shareholders of Sana Biotechnology, Inc.(SANA) of a Class Action Lawsuit and an Upcoming Deadline
- NEW YORK, NY / ACCESS Newswire / April 14, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=142947&wire=1 or contact Joseph E. Levi, Esq.
- 04/14/2025
|
SANA Investors Have Opportunity to Lead Sana Biotechnology, Inc. Securities Fraud Lawsuit with the Schall Law Firm
- LOS ANGELES , April 14, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ: SANA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 17, 2023 and November 4, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before May 20, 2025.
- 04/14/2025
|
Levi & Korsinsky Reminds Sana Biotechnology, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 20, 2025 - SANA
- NEW YORK, NY / ACCESS Newswire / April 14, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=142836&wire=1 or contact Joseph E. Levi, Esq.
- 04/14/2025
|
SANA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sana Biotechnology, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESS Newswire / April 14, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ:SANA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period").
- 04/14/2025
|
Levi & Korsinsky Reminds Sana Biotechnology, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 20, 2025 - SANA
- NEW YORK, NY / ACCESS Newswire / April 13, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=142799&wire=1 or contact Joseph E. Levi, Esq.
- 04/13/2025
|
May 20, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against SANA
- NEW YORK, NY / ACCESS Newswire / April 13, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=142786&wire=1 or contact Joseph E. Levi, Esq.
- 04/13/2025
|
SANA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sana Biotechnology, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
- NEW YORK, April 13, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sana Biotechnology, Inc. (“Sana” or “the Company”) (NASDAQ: SANA) and certain of its officers.
- 04/13/2025
|
Investors in Sana Biotechnology, Inc. Should Contact Levi & Korsinsky Before May 20, 2025 to Discuss Your Rights - SANA
- NEW YORK, NY / ACCESS Newswire / April 13, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=142742&wire=1 or contact Joseph E. Levi, Esq.
- 04/13/2025
|
SANA Investors Have Opportunity to Lead Sana Biotechnology, Inc. Securities Fraud Lawsuit
- NEW YORK , April 13, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sana Biotechnology, Inc. (NASDAQ: SANA) between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period"), of the important May 20, 2025 lead plaintiff deadline. So what: If you purchased Sana securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 04/13/2025
|
Investors in Sana Biotechnology, Inc. Should Contact Levi & Korsinsky Before May 20, 2025 to Discuss Your Rights - SANA
- NEW YORK, NY / ACCESS Newswire / April 13, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=142734&wire=1 or contact Joseph E. Levi, Esq.
- 04/13/2025
|
SANA Investors Have the Opportunity to Lead the Sana Biotechnology Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
- Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Sana To Contact Him Directly To Discuss Their Options
- 04/13/2025
|
Sana Biotechnology, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before May 20, 2025 to Discuss Your Rights - SANA
- NEW YORK, NY / ACCESS Newswire / April 13, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=142697&wire=1 or contact Joseph E. Levi, Esq.
- 04/13/2025
|
SANA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sana Biotechnology, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESS Newswire / April 13, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ:SANA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period").
- 04/13/2025
|
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 20, 2025 in Sana Biotechnology, Inc. Lawsuit - SANA
- NEW YORK CITY, NY / ACCESS Newswire / April 12, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=142666&wire=1 or contact Joseph E. Levi, Esq.
- 04/12/2025
|
Sana Biotechnology, Inc. Class Action: Levi & Korsinsky Reminds Sana Biotechnology, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 20, 2025 - SANA
- NEW YORK CITY, NY / ACCESS Newswire / April 12, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=142636&wire=1 or contact Joseph E. Levi, Esq.
- 04/12/2025
|
Contact Levi & Korsinsky by May 20, 2025 Deadline to Join Class Action Against Sana Biotechnology, Inc. (SANA)
- NEW YORK, NY / ACCESS Newswire / April 11, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=142593&wire=1 or contact Joseph E. Levi, Esq.
- 04/11/2025
|
Sana Biotechnology, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before May 20, 2025 to Discuss Your Rights - SANA
- NEW YORK, NY / ACCESS Newswire / April 11, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=142553&wire=1 or contact Joseph E. Levi, Esq.
- 04/11/2025
|
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Sana Biotechnology, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SANA
- NEW YORK CITY, NY / ACCESS Newswire / April 11, 2025 / WHY: New York, N.Y., April 11, 2025.
- 04/11/2025
|
Contact Levi & Korsinsky by May 20, 2025 Deadline to Join Class Action Against Sana Biotechnology, Inc. (SANA)
- NEW YORK, NY / ACCESS Newswire / April 11, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=142531&wire=1 or contact Joseph E. Levi, Esq.
- 04/11/2025
|
Lost Money on Sana Biotechnology, Inc.(SANA)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESS Newswire / April 11, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=142430&wire=1 or contact Joseph E. Levi, Esq.
- 04/11/2025
|
SANA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sana Biotechnology, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESS Newswire / April 11, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ:SANA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period").
- 04/11/2025
|
Class Action Filed Against Sana Biotechnology, Inc. (SANA) Seeking Recovery for Investors - Contact Levi & Korsinsky
- NEW YORK , April 11, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sana Biotechnology, Inc. investors who were adversely affected by alleged securities fraud between March 17, 2023 and November 4, 2024.
- 04/11/2025
|
Sana Biotechnology, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - SANA
- NEW YORK, NY / ACCESS Newswire / April 10, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=142380&wire=1 or contact Joseph E. Levi, Esq.
- 04/10/2025
|
Levi & Korsinsky Reminds Sana Biotechnology, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 20, 2025 - SANA
- NEW YORK, NY / ACCESS Newswire / April 10, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=142357&wire=1 or contact Joseph E. Levi, Esq.
- 04/10/2025
|
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Sana Biotechnology, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SANA
- NEW YORK CITY, NY / ACCESS Newswire / April 10, 2025 / WHY: New York, N.Y., April 10, 2025.
- 04/10/2025
|
SANA LAWSUIT ALERT: Levi & Korsinsky Notifies Sana Biotechnology, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
- NEW YORK, NY / ACCESS Newswire / April 10, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=142217&wire=1 or contact Joseph E. Levi, Esq.
- 04/10/2025
|
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers - SANA
- NEW YORK, NY / ACCESS Newswire / April 10, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA) and certain officers. The class action, filed in the United States District Court for the Western District of Washington, and docketed under 25-cv-00512, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against Sana and certain of its top officials.
- 04/10/2025
|
Shareholders that Lost Money on Sana Biotechnology, Inc. (SANA) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
- NEW YORK, NY / ACCESS Newswire / April 10, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=142159&wire=1 or contact Joseph E. Levi, Esq.
- 04/10/2025
|
SANA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sana Biotechnology, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESS Newswire / April 10, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ:SANA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period").
- 04/10/2025
|
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 20, 2025 in Sana Biotechnology, Inc. Lawsuit - SANA
- NEW YORK , April 10, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA). Shareholders who purchased shares of SANA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
- 04/10/2025
|
Shareholders of Sana Biotechnology, Inc. Should Contact Levi & Korsinsky Before May 20, 2025 to Discuss Your Rights - SANA
- NEW YORK, NY / ACCESS Newswire / April 9, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=142141&wire=1 or contact Joseph E. Levi, Esq.
- 04/09/2025
|
ROSEN, A LEADING AND RANKED FIRM, Encourages Sana Biotechnology, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SANA
- NEW YORK, April 09, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sana Biotechnology, Inc. (NASDAQ: SANA) between March 17, 2023 and November 4, 2024, inclusive (the “Class Period”), of the important May 20, 2025 lead plaintiff deadline.
- 04/09/2025
|
Lost Money on Sana Biotechnology, Inc. (SANA)? Join Class Action Suit Seeking Recovery – Contact The Gross Law Firm
- NEW YORK, April 09, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA).
- 04/09/2025
|
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 20, 2025 in Sana Biotechnology, Inc. Lawsuit - SANA
- NEW YORK, NY / ACCESS Newswire / April 9, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=142040&wire=1 or contact Joseph E. Levi, Esq.
- 04/09/2025
|
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sana Biotechnology
- Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Sana To Contact Him Directly To Discuss Their Options
- 04/09/2025
|
Sana Biotechnology, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - SANA
- NEW YORK, NY / ACCESS Newswire / April 9, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=142013&wire=1 or contact Joseph E. Levi, Esq.
- 04/09/2025
|
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers - SANA
- NEW YORK, NY / ACCESS Newswire / April 9, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA) and certain officers. The class action, filed in the United States District Court for the Western District of Washington, and docketed under 25-cv-00512, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against Sana and certain of its top officials.
- 04/09/2025
|
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Sana Biotechnology, Inc.(SANA) Shareholders
- NEW YORK, NY / ACCESS Newswire / April 9, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=141900&wire=1 or contact Joseph E. Levi, Esq.
- 04/09/2025
|
SANA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sana Biotechnology, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESS Newswire / April 9, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ:SANA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period").
- 04/09/2025
|
Class Action Filed Against Sana Biotechnology, Inc. (SANA) Seeking Recovery for Investors - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESS Newswire / April 8, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=141828&wire=1 or contact Joseph E. Levi, Esq.
- 04/08/2025
|
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Sana Biotechnology, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SANA
- NEW YORK, NY / ACCESS Newswire / April 8, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sana Biotechnology, Inc. (NASDAQ:SANA) between March 17, 2023 and November 4, 2024, inclusive (the "Class Period"), of the important May 20, 2025 lead plaintiff deadline. SO WHAT: If you purchased Sana securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 04/08/2025
|
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers - SANA
- NEW YORK , April 8, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ: SANA) and certain officers. The class action, filed in the United States District Court for the Western District of Washington, and docketed under 25-cv-00512, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against Sana and certain of its top officials.
- 04/08/2025
|
Levi & Korsinsky Notifies Sana Biotechnology, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - SANA
- NEW YORK, NY / ACCESS Newswire / April 8, 2025 / If you suffered a loss on your Sana Biotechnology, Inc (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=141693&wire=1 or contact Joseph E. Levi, Esq.
- 04/08/2025
|
SANA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sana Biotechnology, Inc. Investors Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESS Newswire / April 8, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ:SANA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period").
- 04/08/2025
|
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 20, 2025 in Sana Biotechnology, Inc. Lawsuit - SANA
- NEW YORK , April 8, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sana Biotechnology, Inc. investors who were adversely affected by alleged securities fraud between March 17, 2023 and November 4, 2024.
- 04/08/2025
|
Levi & Korsinsky Notifies Shareholders of Sana Biotechnology, Inc.(SANA) of a Class Action Lawsuit and an Upcoming Deadline
- NEW YORK, NY / ACCESS Newswire / April 7, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=141561&wire=1 or contact Joseph E. Levi, Esq.
- 04/07/2025
|
SANA Stockholders Should Contact Shareholder Rights Law Firm Robbins LLP for Information on How to Lead the Class Action Against Sana Biotechnology, Inc.
- SAN DIEGO, April 07, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Sana Biotechnology, Inc. (NASDAQ: SANA) securities between March 17, 2023 and November 4, 2024. Sana is a biotechnology company that develops ex vivo and in vivo cell engineering programs to purportedly revolutionize treatment across a broad array of therapeutic areas with unmet treatment needs, including, inter alia, oncology, diabetes, central nervous system (“CNS”) disorders, and B-cell-mediated autoimmune diseases.
- 04/07/2025
|
Levi & Korsinsky Notifies Sana Biotechnology, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - SANA
- NEW YORK, NY / ACCESS Newswire / April 7, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=141500&wire=1 or contact Joseph E. Levi, Esq.
- 04/07/2025
|
SANA Investors Have Opportunity to Lead Sana Biotechnology, Inc. Securities Fraud Lawsuit with the Schall Law Firm
- LOS ANGELES , April 7, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ: SANA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 17, 2023 and November 4, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before May 20, 2025.
- 04/07/2025
|
Levi & Korsinsky Notifies Shareholders of Sana Biotechnology, Inc. (SANA) of a Class Action Lawsuit and an Upcoming Deadline
- NEW YORK, NY / ACCESS Newswire / April 7, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=141426&wire=1 or contact Joseph E. Levi, Esq.
- 04/07/2025
|
SANA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sana Biotechnology, Inc. Investors Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESS Newswire / April 7, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ:SANA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period").
- 04/07/2025
|
Shareholders of Sana Biotechnology, Inc. Should Contact The Gross Law Firm Before May 20, 2025 to Discuss Your Rights - SANA
- NEW YORK , April 7, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA). Shareholders who purchased shares of SANA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
- 04/07/2025
|
SANA LAWSUIT ALERT: Levi & Korsinsky Notifies Sana Biotechnology, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
- NEW YORK, NY / ACCESS Newswire / April 6, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=141362&wire=1 or contact Joseph E. Levi, Esq.
- 04/06/2025
|
SANA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sana Biotechnology, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
- NEW YORK, April 06, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sana Biotechnology, Inc. (“Sana” or “the Company”) (NASDAQ: SANA) and certain of its officers.
- 04/06/2025
|
ROSEN, A LEADING LAW FIRM, Encourages Sana Biotechnology, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SANA
- NEW YORK, NY / ACCESS Newswire / April 6, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sana Biotechnology, Inc. (NASDAQ: SANA) between March 17, 2023 and November 4, 2024, inclusive (the "Class Period"), of the important May 20, 2025 lead plaintiff deadline. SO WHAT: If you purchased Sana securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 04/06/2025
|
Levi & Korsinsky Notifies Shareholders of Sana Biotechnology, Inc.(SANA) of a Class Action Lawsuit and an Upcoming Deadline
- NEW YORK, NY / ACCESS Newswire / April 6, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=141321&wire=1 or contact Joseph E. Levi, Esq.
- 04/06/2025
|
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers - SANA
- NEW YORK CITY, NY / ACCESS Newswire / April 6, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA) and certain officers. The class action, filed in the United States District Court for the Western District of Washington, and docketed under 25-cv-00512, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against Sana and certain of its top officials.
- 04/06/2025
|
Sana Biotechnology, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before May 20, 2025 to Discuss Your Rights - SANA
- NEW YORK, NY / ACCESS Newswire / April 6, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=141262&wire=1 or contact Joseph E. Levi, Esq.
- 04/06/2025
|
Faruqi & Faruqi Reminds Sana Biotechnology Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 20, 2025 - SANA
- Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Sana To Contact Him Directly To Discuss Their Options
- 04/06/2025
|
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Sana Biotechnology, Inc.(SANA) Shareholders
- NEW YORK, NY / ACCESS Newswire / April 6, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=141233&wire=1 or contact Joseph E. Levi, Esq.
- 04/06/2025
|
SANA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sana Biotechnology, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESS Newswire / April 6, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ:SANA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period").
- 04/06/2025
|
Shareholders of Sana Biotechnology, Inc. Should Contact Levi & Korsinsky Before May 20, 2025 to Discuss Your Rights – SANA
- NEW YORK, NY / ACCESS Newswire / April 5, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=141198&wire=1 or contact Joseph E. Levi, Esq.
- 04/05/2025
|
Sana Biotechnology, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before May 20, 2025 to Discuss Your Rights - SANA
- NEW YORK, NY / ACCESS Newswire / April 5, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=141193&wire=1 or contact Joseph E. Levi, Esq.
- 04/05/2025
|
Class Action Filed Against Sana Biotechnology, Inc. (SANA) Seeking Recovery for Investors - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESS Newswire / April 5, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=141157&wire=1 or contact Joseph E. Levi, Esq.
- 04/05/2025
|
ROSEN, GLOBAL INVESTOR RIGHTS COUNSEL, Encourages Sana Biotechnology, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SANA
- NEW YORK, NY / ACCESS Newswire / April 5, 2025 / WHY: New York, N.Y., April 4, 2025.
- 04/05/2025
|
Class Action Filed Against Sana Biotechnology, Inc. (SANA) - May 20, 2025 Deadline to Join – Contact Levi & Korsinsky
- NEW YORK, April 04, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit.
- 04/04/2025
|
Levi & Korsinsky Notifies Shareholders of Sana Biotechnology, Inc. (SANA) of a Class Action Lawsuit and an Upcoming Deadline
- NEW YORK, NY / ACCESS Newswire / April 4, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=141069&wire=1 or contact Joseph E. Levi, Esq.
- 04/04/2025
|
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers - SANA
- NEW YORK CITY, NY / ACCESS Newswire / April 4, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA) and certain officers. The class action, filed in the United States District Court for the Western District of Washington, and docketed under 25-cv-00512, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against Sana and certain of its top officials.
- 04/04/2025
|
Shareholders of Sana Biotechnology, Inc. Should Contact Levi & Korsinsky Before May 20, 2025 to Discuss Your Rights - SANA
- NEW YORK, NY / ACCESS Newswire / April 4, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=140952&wire=1 or contact Joseph E. Levi, Esq.
- 04/04/2025
|
SANA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sana Biotechnology, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESS Newswire / April 4, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ:SANA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period").
- 04/04/2025
|
Contact Levi & Korsinsky by May 20, 2025 Deadline to Join Class Action Against Sana Biotechnology, Inc.(SANA)
- NEW YORK , April 4, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sana Biotechnology, Inc. investors who were adversely affected by alleged securities fraud between March 17, 2023 and November 4, 2024.
- 04/04/2025
|
Sana Biotechnology, Inc. Class Action: Levi & Korsinsky Reminds Sana Biotechnology, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 20, 2025 - SANA
- NEW YORK, NY / ACCESS Newswire / April 4, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=140899&wire=1 or contact Joseph E. Levi, Esq.
- 04/04/2025
|
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sana Biotechnology
- NEW YORK, NY / ACCESS Newswire / April 4, 2025 / Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Sana To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Sana between March 17, 2023 and November 4, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA) and reminds investors of the May 20, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
- 04/04/2025
|
Contact Levi & Korsinsky by May 20, 2025 Deadline to Join Class Action Against Sana Biotechnology, Inc.(SANA)
- NEW YORK, NY / ACCESS Newswire / April 3, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=140815&wire=1 or contact Joseph E. Levi, Esq.
- 04/03/2025
|
SANA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sana Biotechnology, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
- NEW YORK , April 3, 2025 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ: SANA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period").
- 04/03/2025
|
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Sana Biotechnology, Inc. (SANA) Shareholders
- NEW YORK, NY / ACCESS Newswire / April 3, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=140782&wire=1 or contact Joseph E. Levi, Esq.
- 04/03/2025
|
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Sana Biotechnology, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SANA
- NEW YORK CITY, NY / ACCESS Newswire / April 3, 2025 / WHY: New York, N.Y., April 3, 2025.
- 04/03/2025
|
Lost Money on Sana Biotechnology, Inc. (SANA)? Join Class Action Suit Seeking Recovery – Contact The Gross Law Firm
- NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA).
- 04/03/2025
|
Shareholders That Lost Money on Sana Biotechnology, Inc. (SANA) Should Contact Levi & Korsinsky about Pending Class Action - SANA
- NEW YORK, NY / ACCESS Newswire / April 3, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=140629&wire=1 or contact Joseph E. Levi, Esq.
- 04/03/2025
|
SANA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sana Biotechnology, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESS Newswire / April 3, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ:SANA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period").
- 04/03/2025
|
Shareholders of Sana Biotechnology, Inc. Should Contact The Gross Law Firm Before May 20, 2025 to Discuss Your Rights - SANA
- NEW YORK , April 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA). Shareholders who purchased shares of SANA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
- 04/03/2025
|
Shareholders that lost money on Sana Biotechnology, Inc.(SANA) should contact Levi & Korsinsky about pending Class Action - SANA
- NEW YORK, NY / ACCESS Newswire / April 2, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=140614&wire=1 or contact Joseph E. Levi, Esq.
- 04/02/2025
|
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Sana Biotechnology, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SANA
- NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Sana Biotechnology, Inc. (NASDAQ: SANA) between March 17, 2023 and November 17, 2024, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 20, 2025.
- 04/02/2025
|
Contact Levi & Korsinsky by May 20, 2025 Deadline to Join Class Action Against Sana Biotechnology, Inc. (SANA)
- NEW YORK CITY, NY / ACCESS Newswire / April 2, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=140608&wire=1 or contact Joseph E. Levi, Esq.
- 04/02/2025
|
Sana Biotechnology, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before May 20, 2025 to Discuss Your Rights - SANA
- NEW YORK, NY / ACCESS Newswire / April 2, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=140599&wire=1 or contact Joseph E. Levi, Esq.
- 04/02/2025
|
Robbins LLP Reminds SANA Investors with Large Losses to Contact the Firm for Information About the Securities Fraud Class Action Against Sana Biotechnology, Inc.
- SAN DIEGO , April 2, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Sana Biotechnology, Inc. (NASDAQ: SANA) securities between March 17, 2023 and November 4, 2024. Sana is a biotechnology company that develops ex vivo and in vivo cell engineering programs to purportedly revolutionize treatment across a broad array of therapeutic areas with unmet treatment needs, including, inter alia, oncology, diabetes, central nervous system ("CNS") disorders, and B-cell-mediated autoimmune diseases.
- 04/02/2025
|
Levi & Korsinsky Notifies Sana Biotechnology, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - SANA
- NEW YORK, NY / ACCESS Newswire / April 2, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=140503&wire=1 or contact Joseph E. Levi, Esq.
- 04/02/2025
|
Investors in Sana Biotechnology, Inc. Should Contact Levi & Korsinsky Before May 20, 2025 to Discuss Your Rights - SANA
- NEW YORK, NY / ACCESS Newswire / April 2, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=140475&wire=1 or contact Joseph E. Levi, Esq.
- 04/02/2025
|
Sana Biotechnology, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - SANA
- NEW YORK, NY / ACCESS Newswire / April 2, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=140380&wire=1 or contact Joseph E. Levi, Esq.
- 04/02/2025
|
SANA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sana Biotechnology, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESS Newswire / April 2, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ:SANA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period").
- 04/02/2025
|
Levi & Korsinsky Notifies Sana Biotechnology, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - SANA
- NEW YORK, NY / ACCESS Newswire / April 1, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=140237&wire=1 or contact Joseph E. Levi, Esq.
- 04/01/2025
|
SANA Investors Have Opportunity to Lead Sana Biotechnology, Inc. Securities Fraud Lawsuit
- NEW YORK , April 1, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sana Biotechnology, Inc. (NASDAQ: SANA) between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period"), of the important May 20, 2025 lead plaintiff deadline. So what: If you purchased Sana securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 04/01/2025
|
Levi & Korsinsky Notifies Sana Biotechnology, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – SANA
- NEW YORK, April 01, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit.
- 04/01/2025
|
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers - SANA
- NEW YORK, NY / ACCESS Newswire / April 1, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA) and certain officers. The class action, filed in the United States District Court for the Western District of Washington, and docketed under 25-cv-00512, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against Sana and certain of its top officials.
- 04/01/2025
|
Levi & Korsinsky Reminds Sana Biotechnology, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 20, 2025 - SANA
- NEW YORK, NY / ACCESS Newswire / April 1, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=140174&wire=1 or contact Joseph E. Levi, Esq.
- 04/01/2025
|
Class Action Filed Against Sana Biotechnology, Inc. (SANA) - May 20, 2025 Deadline to Join - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESS Newswire / April 1, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=140151&wire=1 or contact Joseph E. Levi, Esq.
- 04/01/2025
|
SANA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sana Biotechnology, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESS Newswire / April 1, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ:SANA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period").
- 04/01/2025
|
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Sana Biotechnology, Inc.(SANA) Shareholders
- NEW YORK , April 1, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sana Biotechnology, Inc. investors who were adversely affected by alleged securities fraud between March 17, 2023 and November 4, 2024.
- 04/01/2025
|
Shareholders that Lost Money on Sana Biotechnology, Inc. (SANA) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
- NEW YORK, NY / ACCESS Newswire / March 31, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=140048&wire=1 or contact Joseph E. Levi, Esq.
- 03/31/2025
|
Sana Biotechnology, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - SANA
- NEW YORK, NY / ACCESS Newswire / March 31, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=140017&wire=1 or contact Joseph E. Levi, Esq.
- 03/31/2025
|
SANA Class Action Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Sana Biotechnology, Inc. Class Action
- SAN DIEGO, CA / ACCESS Newswire / March 31, 2025 / Robbins LLP reminds stockholders that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Sana Biotechnology, Inc. (NASDAQ:SANA) securities between March 17, 2023 and November 4, 2024. Sana is a biotechnology company that develops ex vivo and in vivo cell engineering programs to purportedly revolutionize treatment across a broad array of therapeutic areas with unmet treatment needs, including, inter alia, oncology, diabetes, central nervous system ("CNS") disorders, and B-cell-mediated autoimmune diseases.
- 03/31/2025
|
Contact The Gross Law Firm by May 20, 2025 Deadline to Join Class Action Against Sana Biotechnology, Inc. (SANA)
- NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA).
- 03/31/2025
|
Levi & Korsinsky Reminds Sana Biotechnology, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 20, 2025 - SANA
- NEW YORK, NY / ACCESS Newswire / March 31, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=139986&wire=1 or contact Joseph E. Levi, Esq.
- 03/31/2025
|
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers - SANA
- NEW YORK , March 31, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ: SANA) and certain officers. The class action, filed in the United States District Court for the Western District of Washington, and docketed under 25-cv-00512, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against Sana and certain of its top officials.
- 03/31/2025
|
Sana Biotechnology, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information – SANA
- NEW YORK, NY / ACCESS Newswire / March 31, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=139872&wire=1 or contact Joseph E. Levi, Esq.
- 03/31/2025
|
SANA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sana Biotechnology, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESS Newswire / March 31, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ:SANA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period").
- 03/31/2025
|
The Gross Law Firm Notifies Sana Biotechnology, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - SANA
- NEW YORK , March 31, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA). Shareholders who purchased shares of SANA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
- 03/31/2025
|
Shareholders that lost money on Sana Biotechnology, Inc.(SANA) should contact Levi & Korsinsky about pending Class Action - SANA
- NEW YORK, NY / ACCESS Newswire / March 30, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=139816&wire=1 or contact Joseph E. Levi, Esq.
- 03/30/2025
|
Shareholders that lost money on Sana Biotechnology, Inc.(SANA) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
- NEW YORK, NY / ACCESS Newswire / March 30, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=139783&wire=1 or contact Joseph E. Levi, Esq.
- 03/30/2025
|
SANA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sana Biotechnology, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
- NEW YORK, March 30, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sana Biotechnology, Inc. (“Sana” or “the Company”) (NASDAQ: SANA) and certain of its officers.
- 03/30/2025
|
Levi & Korsinsky Reminds Sana Biotechnology, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 20, 2025 - SANA
- NEW YORK, NY / ACCESS Newswire / March 29, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=139606&wire=1 or contact Joseph E. Levi, Esq.
- 03/29/2025
|
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Sana Biotechnology, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SANA
- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Sana Biotechnology, Inc. (NASDAQ:SANA) between March 17, 2023 and November 17, 2024, inclusive (the "Class Period"). A class action lawsuit has already been filed.
- 03/28/2025
|
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 20, 2025 in Sana Biotechnology, Inc. Lawsuit - SANA
- NEW YORK, NY / ACCESS Newswire / March 28, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=139485&wire=1 or contact Joseph E. Levi, Esq.
- 03/28/2025
|
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sana Biotechnology
- Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Sana To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Sana between March 17, 2023 and November 4, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK,, March 28, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ: SANA) and reminds investors of the May 20, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
- 03/28/2025
|
NVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers - SANA
- NEW YORK, NY / ACCESS Newswire / March 28, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA) and certain officers. The class action, filed in the United States District Court for the Western District of Washington, and docketed under 25-cv-00512, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against Sana and certain of its top officials.
- 03/28/2025
|
Sana Biotechnology, Inc. Class Action: Levi & Korsinsky Reminds Sana Biotechnology, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 20, 2025 - SANA
- NEW YORK, NY / ACCESS Newswire / March 28, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=139367&wire=1 or contact Joseph E. Levi, Esq.
- 03/28/2025
|
SANA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sana Biotechnology, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESS Newswire / March 28, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ:SANA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period").
- 03/28/2025
|
Class Action Filed Against Sana Biotechnology, Inc. (SANA) Seeking Recovery for Investors - Contact Levi & Korsinsky
- NEW YORK , March 28, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sana Biotechnology, Inc. investors who were adversely affected by alleged securities fraud between March 17, 2023 and November 4, 2024.
- 03/28/2025
|
Levi & Korsinsky Reminds Sana Biotechnology, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 20, 2025 – SANA
- NEW YORK, NY / ACCESS Newswire / March 27, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=139294&wire=1 or contact Joseph E. Levi, Esq.
- 03/27/2025
|
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers – SANA
- NEW YORK, NY / ACCESS Newswire / March 27, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA) and certain officers. The class action, filed in the United States District Court for the Western District of Washington, and docketed under 25-cv-00512, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against Sana and certain of its top officials.
- 03/27/2025
|
Levi & Korsinsky Notifies Shareholders of Sana Biotechnology, Inc. (SANA) of a Class Action Lawsuit and an Upcoming Deadline
- NEW YORK, NY / ACCESS Newswire / March 27, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=139210&wire=1 or contact Joseph E. Levi, Esq.
- 03/27/2025
|
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sana Biotechnology
- Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Sana To Contact Him Directly To Discuss Their Options
- 03/27/2025
|
Lost Money on Sana Biotechnology, Inc. (SANA)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESS Newswire / March 27, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=139204&wire=1 or contact Joseph E. Levi, Esq.
- 03/27/2025
|
Lost Money on Sana Biotechnology, Inc. (SANA)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky
- NEW YORK, March 27, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit.
- 03/27/2025
|
Levi & Korsinsky Notifies Sana Biotechnology, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - SANA
- NEW YORK, NY / ACCESS Newswire / March 27, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=139138&wire=1 or contact Joseph E. Levi, Esq.
- 03/27/2025
|
Levi & Korsinsky Reminds Sana Biotechnology, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 20, 2025 - SANA
- NEW YORK, NY / ACCESS Newswire / March 27, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=139062&wire=1 or contact Joseph E. Levi, Esq.
- 03/27/2025
|
SANA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sana Biotechnology, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESS Newswire / March 27, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ:SANA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period").
- 03/27/2025
|
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 20, 2025 in Sana Biotechnology, Inc. Lawsuit - SANA
- NEW YORK , March 27, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA). Shareholders who purchased shares of SANA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
- 03/27/2025
|
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Sana Biotechnology, Inc.(SANA) Shareholders
- NEW YORK, NY / ACCESS Newswire / March 26, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=139015&wire=1 or contact Joseph E. Levi, Esq.
- 03/26/2025
|
Sana Biotechnology, Inc. Stockholder News: Robbins LLP Reminds Investors of the Class Action Lawsuit Against SANA
- SAN DIEGO, March 26, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Sana Biotechnology, Inc. (NASDAQ: SANA) securities between March 17, 2023 and November 4, 2024. Sana is a biotechnology company that develops ex vivo and in vivo cell engineering programs to purportedly revolutionize treatment across a broad array of therapeutic areas with unmet treatment needs, including, inter alia, oncology, diabetes, central nervous system (“CNS”) disorders, and B-cell-mediated autoimmune diseases.
- 03/26/2025
|
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 20, 2025 in Sana Biotechnology, Inc. Lawsuit - SANA
- NEW YORK, NY / ACCESS Newswire / March 26, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=138975&wire=1 or contact Joseph E. Levi, Esq.
- 03/26/2025
|
SANA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sana Biotechnology, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
- NEW YORK , March 26, 2025 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ: SANA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period").
- 03/26/2025
|
Levi & Korsinsky Reminds Sana Biotechnology, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 20, 2025 - SANA
- NEW YORK, NY / ACCESS Newswire / March 26, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=138950&wire=1 or contact Joseph E. Levi, Esq.
- 03/26/2025
|
ROSEN, LEADING INVESTOR COUNSEL, Encourages Sana Biotechnology, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SANA
- NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Sana Biotechnology, Inc. (NASDAQ: SANA) between March 17, 2023 and November 17, 2024, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 20, 2025.
- 03/26/2025
|
Shareholders that lost money on Sana Biotechnology, Inc. (SANA) should contact The Gross Law Firm about pending Class Action - SANA
- NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA).
- 03/26/2025
|
Investors in Sana Biotechnology, Inc. Should Contact Levi & Korsinsky Before May 20, 2025 to Discuss Your Rights - SANA
- NEW YORK, NY / ACCESS Newswire / March 26, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=138796&wire=1 or contact Joseph E. Levi, Esq.
- 03/26/2025
|
Class Action Filed Against Sana Biotechnology, Inc. (SANA) - May 20, 2025 Deadline to Join - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESS Newswire / March 26, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=138751&wire=1 or contact Joseph E. Levi, Esq.
- 03/26/2025
|
SANA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sana Biotechnology, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESS Newswire / March 26, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ:SANA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period").
- 03/26/2025
|
Class Action Filed Against Sana Biotechnology, Inc. (SANA) - May 20, 2025 Deadline to Join - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESS Newswire / March 26, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=138737&wire=1 or contact Joseph E. Levi, Esq.
- 03/26/2025
|
SANA Investors Have Opportunity to Lead Sana Biotechnology, Inc. Securities Fraud Lawsuit
- NEW YORK , March 26, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers and acquirers of Sana Biotechnology, Inc. (NASDAQ: SANA) securities between March 17, 2023 and November 17, 2024, inclusive (the "Class Period"). A class action lawsuit has already been filed.
- 03/26/2025
|
Class Action Filed Against Sana Biotechnology, Inc. (SANA) - May 20, 2025 Deadline to Join - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESS Newswire / March 25, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=138646&wire=1 or contact Joseph E. Levi, Esq.
- 03/25/2025
|
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers - SANA
- NEW YORK , March 25, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ: SANA) and certain officers. The class action, filed in the United States District Court for the Western District of Washington, and docketed under 25-cv-00512, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against Sana and certain of its top officials.
- 03/25/2025
|
Sana Biotechnology, Inc. Class Action: Levi & Korsinsky Reminds Sana Biotechnology, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 20, 2025 - SANA
- NEW YORK, NY / ACCESS Newswire / March 25, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=138534&wire=1 or contact Joseph E. Levi, Esq.
- 03/25/2025
|
SANA Investors Have Opportunity to Lead Sana Biotechnology, Inc. Securities Fraud Lawsuit with the Schall Law Firm
- LOS ANGELES , March 25, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ: SANA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 17, 2023 and November 4, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before May 20, 2025.
- 03/25/2025
|
Levi & Korsinsky Reminds Sana Biotechnology, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 20, 2025 - SANA
- NEW YORK, NY / ACCESS Newswire / March 25, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=138465&wire=1 or contact Joseph E. Levi, Esq.
- 03/25/2025
|
SANA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sana Biotechnology, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESS Newswire / March 25, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ:SANA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period").
- 03/25/2025
|
Sana Biotechnology: High-Risk High-Reward With Breakthrough UP421
- SANA develops engineered cell therapies for diabetes, autoimmune diseases, and cancer using ex vivo HIP and in vivo fusogen platforms. SC291 is their CD19‑targeted allogeneic CAR-T candidate which also received FDA Fast Track for r/r SLE, extrarenal lupus, and lupus nephritis. However, UP421 might be the most promising. It restored insulin production in a type 1 diabetes patient.
- 03/24/2025
|
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers - SANA
- NEW YORK, NY / ACCESS Newswire / March 24, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA) and certain officers. The class action, filed in the United States District Court for the Western District of Washington, and docketed under 25-cv-00512, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against Sana and certain of its top officials.
- 03/24/2025
|
Class Action Filed Against Sana Biotechnology, Inc. (SANA) Seeking Recovery for Investors - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESS Newswire / March 24, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=138393&wire=1 or contact Joseph E. Levi, Esq.
- 03/24/2025
|
Investor Alert: Robbins LLP Informs Investors of the Sana Biotechnology, Inc. Class Action Lawsuit
- SAN DIEGO , March 24, 2025 /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Sana Biotechnology, Inc. (NASDAQ: SANA) securities between March 17, 2023 and November 4, 2024. Sana is a biotechnology company that develops ex vivo and in vivo cell engineering programs to purportedly revolutionize treatment across a broad array of therapeutic areas with unmet treatment needs, including, inter alia, oncology, diabetes, central nervous system ("CNS") disorders, and B-cell-mediated autoimmune diseases.
- 03/24/2025
|
Class Action Filed Against Sana Biotechnology, Inc. (SANA) Seeking Recovery for Investors – Contact Levi & Korsinsky
- NEW YORK, NY / ACCESS Newswire / March 24, 2025 / If you suffered a loss on your Sana Biotechnology, Inc. (NASDAQ:SANA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sana-biotechnology-inc-lawsuit-submission-form?prid=138354&wire=1 or contact Joseph E. Levi, Esq.
- 03/24/2025
|
SANA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sana Biotechnology, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
- NEW YORK, March 24, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sana Biotechnology, Inc. (“Sana” or “the Company”) (NASDAQ: SANA) and certain of its officers.
- 03/24/2025
|
Rosen Law Firm Urges Sana Biotechnology, Inc. (NASDAQ: SANA) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
- NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers and acquirers of Sana Biotechnology, Inc. (NASDAQ: SANA) securities between March 17, 2023 and November 17, 2024, inclusive (the “Class Period”). Sana is a biotechnology company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations tha.
- 03/24/2025
|
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers - SANA
- NEW YORK, NY / ACCESS Newswire / March 24, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA) and certain officers. The class action, filed in the United States District Court for the Western District of Washington, and docketed under 25-cv-00512, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against Sana and certain of its top officials.
- 03/24/2025
|
SANA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sana Biotechnology, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
- NEW YORK, NY / ACCESS Newswire / March 24, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ:SANA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period").
- 03/24/2025
|
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Sana Biotechnology, Inc. (SANA) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm
- ATLANTA, March 24, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Sana Biotechnology, Inc. (“Sana” or the “Company”) (NASDAQ: SANA). The lawsuit alleges that Defendants made false and/or misleading statements and/or failed to disclose material facts regarding Sana's business, operations, and prospects, including allegations that: (i) Sana was at significant risk of having insufficient funds to maintain its current operations and advance one or more of its product candidates; (ii) SC291 in oncology, SC379, and SG299 were less promising than Defendants had led investors to believe; (iii) in order to preserve cash and advance its more promising product candidates, Sana was likely to decrease funding for and/or discontinue SC291 in oncology, SC379, and SG299, as well as significantly reduce its headcount; and (iv) accordingly, Defendants overstated Sana's financial capacity to maintain its current operations and advance its existing product candidates.
- 03/24/2025
|
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Sana Biotechnology, Inc. (SANA)
- NEW YORK, March 24, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Western District of Washington on behalf of all persons or entities who purchased or otherwise acquired Sana Biotechnology, Inc. (“Sana” or the “Company”) (NASDAQ: SANA) securities between March 17, 2023 and November 4, 2024, inclusive (the “Class Period”). The lawsuit seeks to recover damages for the Company's investors under the federal securities laws.
- 03/24/2025
|
SANA Investors Have Opportunity to Lead Sana Biotechnology, Inc. Securities Fraud Lawsuit with the Schall Law Firm
- LOS ANGELES--(BUSINESS WIRE)--SANA Investors Have Opportunity to Lead Sana Biotechnology, Inc. Securities Fraud Lawsuit with the Schall Law Firm.
- 03/23/2025
|
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers – SANA
- NEW YORK, NY / ACCESS Newswire / March 21, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA) and certain officers. The class action, filed in the United States District Court for the Western District of Washington, and docketed under 25-cv-00512, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against Sana and certain of its top officials.
- 03/21/2025
|
Sana Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
- Announced positive preliminary 12-week clinical results, building on already released 4-week results, of ongoing type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression overcome autoimmune and allogeneic immune recognition, function, and persist with stable C-peptide production post-transplant
- 03/17/2025
|
Sana Biotechnology to Present at the Cowen 45th Annual Health Care Conference
- SEATTLE, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the Cowen 45th Annual Health Care Conference at 3:10 p.m. ET on Monday, March 3, 2025. The presentation will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer.
- 02/24/2025
|
There May Still Be Time to Get in on These 3 Trending Biotechs
- Despite the strength of the economy overall, 2024 was a challenging year for the biotech industry. The high cost of borrowing—particularly prior to the Fed's first rate cut in several years in September—coupled with a shifting landscape for the healthcare sector dampened prospects for many firms.
- 01/20/2025
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA
- NEW YORK, NY / ACCESS Newswire / January 18, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 01/18/2025
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA
- NEW YORK, NY / ACCESS Newswire / January 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 01/16/2025
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA
- NEW YORK, NY / ACCESSWIRE / January 10, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 01/10/2025
|
SANA Stock Surges 152% in a Week on Upbeat Initial Diabetes Study Data
- Sana stock soars in a week following positive initial data from a first-in-human study of investigational cell therapy, UP421, in diabetes patients.
- 01/10/2025
|
Sana Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- SEATTLE, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the 43rd Annual J.P. Morgan Healthcare Conference at 9:00 a.m. PT on Wednesday, January 15, 2025. The presentation will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer.
- 01/08/2025
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA
- NEW YORK , Jan. 8, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ: SANA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 01/08/2025
|
Sana Biotechnology skyrockets 200% on positive diabetes study data
- Sana Biotechnology Inc skyrocketed over 200% on Wednesday after unveiling positive results from its first in-human diabetes trial. No safety issues were observed four weeks after transplanting Sana's UP421 allogeneic primary islet cell therapy into a type 1 diabetes patient, a statement said.
- 01/08/2025
|
Sana Biotechnology: Stock Price Rise Deserved Post Diabetes Cell Therapy Success
- Sana Biotechnology, Inc. stock will be surging today after the company showed it can safely administer its allogeneic cell therapy for diabetes to a patient with no immunosuppression. Engineered cells were accepted by the patient's immune system without immunosuppression, a potential game-changing breakthrough that has stumped scientists for >75 years. Although the data is from a single patient, the potential market opportunity for a functional cure for Type 1 diabetes is immense.
- 01/08/2025
|
Sana Biotechnology Stock Surges Over 200% On Wednesday - Here's Why
- On Tuesday, Sana Biotechnology Inc SANA released the initial results from a first-in-human study transplanting UP421, an allogeneic primary islet cell therapy engineered with Sana's hypoimmune (HIP) technology, into a type 1 diabetes patient without the use of any immunosuppression.
- 01/08/2025
|
Citi keeps $15 target on Sana, says data 'potentially transformative'
- Citi says that while the wait for Sana Biotechnology's initial type 1 diabetes data was long, the "reward was well worth it as Sana has delivered what looks to be potentially transformative data," the analyst tells investors in a research note. The data demonstrate a "major scientific advance" for type 1 diabetes patients as it suggests Sana's hypoimmune edits permit islet cell transplant survival in the absence of immunosuppression, the analyst tells investors in a research note. Citi believes the implications extend beyond type 1 diabetes and islet cells though, and could potentially be applied broadly within the allogeneic field. The firm anticipates the stock could continue to appreciate after the open today and keeps a Buy rating on the name with a $15 price target. Sana in premarket trading is up 274%, or $4.52, to $6.17.
- 01/08/2025
|
H.C. Wainwright ups Sana target after 'best case scenario' data
- H.C. Wainwright raised the firm's price target on Sana Biotechnology to $11 from $8 and keeps a Buy rating on the shares. The firm increased its probability of sucess for SC451 to 15% from 10% based on today's data and for SC291 for autoimmune diseases to 20% from 15% based on the Phase 1 data and progress from competitor allogeneic CAR-T programs in the space. The first patient dosed with hypoimmune islet cells showcased cell survive and function without immunosuppression, the analyst tells investors in a research note. H.C. Wainwright says the patient met all the primary and secondary trial endpoints. It views the data as the "best case scenario" for the initial type 1 diabetes update.
- 01/08/2025
|
This Biotech Stock Just Soared 240%. Why It Can Go Higher.
- The shares are at about $5 now, and strategists see a chance they could go to $10.
- 01/08/2025
|
Sana Biotechnology Announces Positive Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression
- First-in-Human Study Provides Evidence that Sana's Hypoimmune (HIP) Technology Enables Transplanted Islet Cells to Avoid Immune Rejection and Produce Insulin Without Immunosuppression
- 01/07/2025
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA
- NEW YORK CITY, NY / ACCESSWIRE / January 6, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 01/06/2025
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA
- NEW YORK, NY / ACCESSWIRE / January 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ: SANA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 01/05/2025
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA
- NEW YORK, NY / ACCESSWIRE / January 3, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 01/03/2025
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA
- NEW YORK , Jan. 2, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ: SANA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 01/02/2025
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA
- NEW YORK, NY / ACCESSWIRE / December 31, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 12/31/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA
- NEW YORK, NY / ACCESSWIRE / December 30, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 12/30/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA
- NEW YORK, NY / ACCESSWIRE / December 29, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ: SANA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 12/29/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA
- NEW YORK , Dec. 27, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ: SANA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 12/27/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA
- NEW YORK, NY / ACCESSWIRE / December 26, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 12/26/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA
- NEW YORK, NY / ACCESSWIRE / December 24, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 12/24/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA
- NEW YORK, NY / ACCESSWIRE / December 17, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 12/17/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA
- NEW YORK, NY / ACCESSWIRE / December 16, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 12/16/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA
- NEW YORK, NY / ACCESSWIRE / December 15, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ: SANA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 12/15/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA
- NEW YORK, NY / ACCESSWIRE / December 13, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 12/13/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA
- NEW YORK, NY / ACCESSWIRE / December 11, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 12/11/2024
|
Sana: Major Inflection Point For SC291 In 2025 Targeting Lupus
- Sana Biotechnology results from the phase 1 study using SC291 for the treatment of patients with SLE are expected in 2025. The FDA's Fast Track Designation for SC291 could expedite its review, addressing unmet medical needs in autoimmune disorders. Sana is also developing SC262 for relapsed/refractory B-cell malignancies, with data expected by the end of 2024 or in 2025.
- 12/04/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA
- NEW YORK , Dec. 3, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ: SANA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 12/03/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA
- NEW YORK CITY, NY / ACCESSWIRE / November 27, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 11/27/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA
- NEW YORK CITY, NY / ACCESSWIRE / November 26, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 11/26/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA
- NEW YORK , Nov. 25, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ: SANA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 11/25/2024
|
Sana Biotechnology to Present at December 2024 Investor Conferences
- SEATTLE, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in December. The presentations will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer.
- 11/25/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA
- NEW YORK, NY / ACCESSWIRE / November 22, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 11/22/2024
|
ATTENTION SANA SHAREHOLDERS: Investors who lost money on Sana Biotechnology, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation
- NEW YORK, NY / ACCESSWIRE / November 21, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sana Biotechnology, Inc. ("Sana Biotechnology, Inc.") (NASDAQ:SANA) concerning possible violations of federal securities laws. Sana issued a press release on November 4, 2024, announcing that it "will suspend development of both SC291 in oncology and of SC379, its glial progenitor cell program, as it seeks partnerships for these programs".
- 11/21/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA
- NEW YORK, NY / ACCESSWIRE / November 20, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 11/20/2024
|
Shareholder Rights Advocates at Levi & Korsinsky Investigate Sana Biotechnology, Inc. (SANA) Regarding Possible Securities Fraud Violations
- NEW YORK, NY / ACCESSWIRE / November 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sana Biotechnology, Inc. ("Sana Biotechnology, Inc.") (NASDAQ:SANA) concerning possible violations of federal securities laws. Sana issued a press release on November 4, 2024, announcing that it "will suspend development of both SC291 in oncology and of SC379, its glial progenitor cell program, as it seeks partnerships for these programs".
- 11/20/2024
|
Sana Biotechnology: The Story Becomes Murkier
- Sana Biotechnology, Inc.'s stock has dropped from around $9 to under $2.50 since mid-March, when we last took a look at this engineered-cell therapy concern. Earlier this month, the company suspended two of its developmental programs to improve its pipeline focus and lower its cash burn rate to extend its “cash runway.”. The analyst community is also quite mixed around Sana Biotechnology's current prospects, but some additional trial data should be posted in the near future.
- 11/19/2024
|
Did Sana Biotechnology, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - SANA
- NEW YORK, NY / ACCESSWIRE / November 19, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sana Biotechnology, Inc. ("Sana Biotechnology, Inc.") (NASDAQ:SANA) concerning possible violations of federal securities laws. Sana issued a press release on November 4, 2024, announcing that it "will suspend development of both SC291 in oncology and of SC379, its glial progenitor cell program, as it seeks partnerships for these programs".
- 11/19/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA
- NEW YORK , Nov. 18, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ: SANA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 11/18/2024
|
Levi & Korsinsky Announces an Investigation on Behalf of Sana Biotechnology, Inc. (SANA) Shareholders Who May Have Been Affected by Fraud
- NEW YORK, NY / ACCESSWIRE / November 18, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sana Biotechnology, Inc. ("Sana Biotechnology, Inc.") (NASDAQ:SANA) concerning possible violations of federal securities laws. Sana issued a press release on November 4, 2024, announcing that it "will suspend development of both SC291 in oncology and of SC379, its glial progenitor cell program, as it seeks partnerships for these programs".
- 11/18/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA
- NEW YORK CITY, NY / ACCESSWIRE / November 16, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 11/16/2024
|
Did Sana Biotechnology, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate– SANA
- NEW YORK, NY / ACCESSWIRE / November 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sana Biotechnology, Inc. ("Sana Biotechnology, Inc.") (NASDAQ:SANA) concerning possible violations of federal securities laws. Sana issued a press release on November 4, 2024, announcing that it "will suspend development of both SC291 in oncology and of SC379, its glial progenitor cell program, as it seeks partnerships for these programs".
- 11/14/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA
- NEW YORK CITY, NY / ACCESSWIRE / November 14, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 11/14/2024
|
Sana Biotechnology, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - SANA
- NEW YORK, NY / ACCESSWIRE / November 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sana Biotechnology, Inc. ("Sana Biotechnology, Inc.") (NASDAQ:SANA) concerning possible violations of federal securities laws. Sana issued a press release on November 4, 2024, announcing that it "will suspend development of both SC291 in oncology and of SC379, its glial progenitor cell program, as it seeks partnerships for these programs".
- 11/14/2024
|
Here's Why Sana (SANA) Could be Great Choice for a Bottom Fisher
- Sana (SANA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
- 11/13/2024
|
Shareholder Rights Advocates at Levi & Korsinsky Investigate Sana Biotechnology, Inc. (SANA) Regarding Possible Securities Fraud Violations
- NEW YORK, NY / ACCESSWIRE / November 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sana Biotechnology, Inc. ("Sana Biotechnology, Inc.") (NASDAQ:SANA) concerning possible violations of federal securities laws. Sana issued a press release on November 4, 2024, announcing that it "will suspend development of both SC291 in oncology and of SC379, its glial progenitor cell program, as it seeks partnerships for these programs".
- 11/12/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA
- NEW YORK, NY / ACCESSWIRE / November 12, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 11/12/2024
|
Sana Biotechnology, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- SANA
- NEW YORK, NY / ACCESSWIRE / November 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sana Biotechnology, Inc. ("Sana Biotechnology, Inc.") (NASDAQ:SANA) concerning possible violations of federal securities laws. Sana issued a press release on November 4, 2024, announcing that it "will suspend development of both SC291 in oncology and of SC379, its glial progenitor cell program, as it seeks partnerships for these programs".
- 11/12/2024
|
Down -24.69% in 4 Weeks, Here's Why Sana (SANA) Looks Ripe for a Turnaround
- Sana (SANA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
- 11/11/2024
|
Sana Biotechnology, Inc. Being Investigated on Behalf of Sana Biotechnology, Inc. Investors. Contact Levi & Korsinsky For Details.
- NEW YORK, NY / ACCESSWIRE / November 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sana Biotechnology, Inc. ("Sana Biotechnology, Inc.") (NASDAQ:SANA) concerning possible violations of federal securities laws. Sana issued a press release on November 4, 2024, announcing that it "will suspend development of both SC291 in oncology and of SC379, its glial progenitor cell program, as it seeks partnerships for these programs".
- 11/11/2024
|
Sana Biotechnology Reports Third Quarter 2024 Financial Results and Business Updates
- Continue to advance hypoimmune technology in three trials across five indications in type 1 diabetes, B-cell mediated autoimmune diseases, and oncology
- 11/08/2024
|
Did Sana Biotechnology, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - SANA
- NEW YORK, NY / ACCESSWIRE / November 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sana Biotechnology, Inc. ("Sana Biotechnology, Inc.") (NASDAQ:SANA) concerning possible violations of federal securities laws. Sana issued a press release on November 4, 2024, announcing that it "will suspend development of both SC291 in oncology and of SC379, its glial progenitor cell program, as it seeks partnerships for these programs".
- 11/07/2024
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA
- NEW YORK, NY / ACCESSWIRE / November 7, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
- 11/07/2024
|
Sana Biotechnology Announces Increased Focus on Type 1 Diabetes and B-cell Mediated Autoimmune Diseases with the Potential to Deliver Clinical Proof of Concept Data Across Multiple Studies in 2024 and 2025
- Prioritize clinical and preclinical development on type 1 diabetes (UP421 and SC451), B-cell mediated autoimmune diseases (SC291), refractory B-cell malignancies (SC262), and the fusogen platform for generating in vivo CAR T cells
- 11/04/2024
|
Sana Biotechnology to Present at the Goldman Sachs Cell Therapy Day Conference
- SEATTLE, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its panel at the Goldman Sachs Cell Therapy Day Conference at 1:00 p.m. ET on Tuesday, October 1, 2024. The presentation will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer.
- 09/30/2024
|
Sana Biotechnology to Present at September 2024 Investor Conferences
- SEATTLE, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at three investor conferences in September. The presentations will feature a business overview and update.
- 08/29/2024
|
Sana Biotechnology Appoints Accomplished Drug Developer Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer
- SEATTLE, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced the appointment of Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer.
- 08/26/2024
|
Sana Biotechnology cuts the ribbon at new manufacturing facility near Seattle
- Sana Biotechnology celebrated the beginning of a new chapter on its journey to make drugs that treat complicated diseases, cutting the ribbon outside the company's new manufacturing facility in Bothell, Wash.
- 08/02/2024
|
SANA Stock Earnings: Sana Biotechnology Meets EPS for Q1 2024
- Sana Biotechnology (NASDAQ: SANA ) just reported results for the first quarter of 2024. Sana Biotechnology reported earnings per share of -32 cents.
- 05/08/2024
|
Sana Biotechnology to Present at May and June 2024 Investor Conferences
- SEATTLE, May 06, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at three investor conferences in May and June. The presentations will feature a business overview and update.
- 05/06/2024
|
4 Stocks to Keep a Tab on for Amazing Earnings Acceleration
- Notable companies to have witnessed solid earnings acceleration as of now are Sana Biotechnology (SANA), LifeMD (LFMD), Evolus (EOLS) and Expro Group Holdings (XPRO).
- 05/03/2024
|
Best biotech stocks to buy and hold in 2024: VKTX, SANA, RXRX
- Biotech stocks are having a relatively strong year as investors focus on the growing M&A in the healthcare space. Johnson & Johnson is acquiring Shockwave Medical while Novo Nordisk is buying Catalent, a CDMO organization.
- 04/21/2024
|
Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
- Goal to treat 40-60 patients in 2024 in four trials across seven indications in oncology, B-cell mediated autoimmune diseases, and type 1 diabetes
- 02/29/2024
|
Sana Biotechnology to Present at the Cowen 44th Annual Health Care Conference
- SEATTLE, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the Cowen 44th Annual Health Care Conference at 2:50 p.m. ET on Wednesday, March 6, 2024. The presentation will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer.
- 02/28/2024
|
Insider Buying: Taking a Controlling Stake in a Struggling Retailer?
- The biggest insider trading news of the week may have been Amazon.com Inc. (NASDAQ: AMZN) founder Jeff Bezos shedding over $4 billion worth of the company's shares as he reportedly prepares to move to Florida to take advantage of the better income tax environment.
- 02/18/2024
|
Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHP
- Transplant of HIP-modified pancreatic islet cells provided lasting glucose control in a fully immunocompetent non-human primate (NHP), enabling the achievement of exogenous insulin independence without immunosuppression for six month study duration
- 02/13/2024
|
Sana Biotechnology Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
- SEATTLE, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it has closed its underwritten upsized public offering of 21,772,728 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 4,500,000 additional shares of its common stock, at a price to the public of $5.50 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 12,727,272 shares of its common stock at a price to the public of $5.4999 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.0001 per share exercise price for each pre-funded warrant. All of the shares and pre-funded warrants were sold by Sana. The gross proceeds from the offering were approximately $189.75 million before deducting underwriting discounts and commissions and other offering expenses.
- 02/12/2024
|
Sana Biotechnology Announces Pricing of Upsized Public Offering
- SEATTLE, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it has priced its underwritten upsized public offering of 17,272,728 shares of its common stock at a price to the public of $5.50 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 12,727,272 shares of common stock at a price to the public of $5.4999 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.0001 per share exercise price for each pre-funded warrant. All of the shares and pre-funded warrants are to be sold by Sana. In addition, Sana has granted the underwriters a 30-day option to purchase up to an additional 4,500,000 shares of its common stock. The gross proceeds from the offering are expected to be approximately $165.0 million before deducting underwriting discounts and commissions and other offering expenses and excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on or about February 12, 2024, subject to satisfaction of customary closing conditions.
- 02/08/2024
|
Sana Biotechnology Announces Proposed Public Offering of Common Stock
- SEATTLE, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it has commenced an underwritten public offering of $125.0 million of shares of its common stock. In addition, Sana intends to grant the underwriters a 30-day option to purchase up to an additional $18.75 million of shares of its common stock. All of the shares to be sold in this offering will be sold by Sana. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the proposed offering.
- 02/07/2024
|
Are You Looking for a Top Momentum Pick? Why Sana Biotechnology (SANA) is a Great Choice
- Does Sana Biotechnology (SANA) have what it takes to be a top stock pick for momentum investors? Let's find out.
- 01/18/2024
|
Sana Bio (SANA) Stock Rallies 105% in 3 Months: Here's Why
- Sana Bio (SANA) rallies 105% after the company reports encouraging pipeline progress with its candidates, SC291 and SC262, for oncology and autoimmune indications.
- 01/18/2024
|
JD Henning Cautious About 2024, An Unusual Year For Market Considerations
- JD Henning discusses his approach to the market and emphasizes the importance of timing and using momentum gauges to avoid major market downturns. Investing vs trading portfolios.
- 01/17/2024
|
Sana Biotechnology: SC291 Moving Forward Beyond Hematological Malignancies
- Additional results from a Sana Biotechnology, Inc. phase 1 study, using SC291 for the treatment of patients with B-cell lymphomas and leukemias, are expected in 2024. Initial results from phase 1 study, using SC291 for the treatment of patients with autoimmune disorders, expected in 2024. Initial results from phase 1 study, using SC262 for the treatment of patients with r/r B-cell Lymphomas who failed prior anti-CD19 therapies, expected in 2024.
- 01/05/2024
|
Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262, a Hypoimmune-modified, CD22-directed Allogeneic CAR T Therapy, for Patients with Relapsed or Refractory B-cell Malignancies
- SEATTLE, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application to initiate a study of SC262 in patients with relapsed or refractory B-cell malignancies, initially in patients who have received prior CD19-directed CAR T therapy. Engineered CAR T cell therapies for B-cell malignancies use binders to target proteins expressed on the surface of B cells.
- 01/05/2024
|
Sana Biotechnology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- SEATTLE, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the 42nd Annual J.P. Morgan Healthcare Conference at 9:45 a.m. PT on Tuesday, January 9, 2024. The presentation will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer.
- 01/03/2024
|
Sana Biotechnology Highlights Preclinical Data Supporting Tumor Control and Immune Evasion Capabilities of Hypoimmune-Modified Allogeneic CAR T Cells in Presentations at the American Society of Hematology Annual Meeting
- Preclinical data with SC262, a HIP-modified CD22-directed allogeneic CAR T cell, further support completed IND submission
- 12/11/2023
|
Sana Biotechnology Publishes Early Clinical Data Showing that SC291, a CD19-directed Allogeneic CAR T Therapy, Evades Immune Detection in Presence of Intact Immune System
- SEATTLE, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced the publication in Blood of an abstract providing initial clinical data from the first patient treated at the lowest dose in the ongoing ARDENT Phase 1 clinical trial with SC291, a hypoimmune (HIP)-modified allogeneic CD19-directed CAR T cell therapy. SC291 appeared safe and well tolerated, evaded immune detection, and induced a partial response in a patient with chronic lymphocytic leukemia (CLL). ARDENT is a Phase 1 study evaluating safety and tolerability of SC291 in patients with CLL and non-Hodgkin lymphoma. Treatment in this dose escalation study is ongoing, and the company expects to present more data from this study at a later date in an appropriate venue.
- 12/01/2023
|
Sana Biotechnology to Present at November and December 2023 Investor Conferences
- SEATTLE, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in November and December. The presentations will feature a business overview and update.
- 11/21/2023
|
Sana Biotechnology to Present at September 2023 Investor Conferences
- SEATTLE, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at five investor conferences in September. The presentations will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer, and Nate Hardy, Sana's Chief Financial Officer.
- 08/30/2023
|
Sana Biotechnology: Hypoimmune Platform Might Stealth Cells
- Results from the phase 1 study using SC291 for the treatment of patients with B-cell lymphomas are expected to be released later in 2023. It is said that the global B-cell lymphoma treatment market could reach $13.14 billion by 2030. The company is testing the use of its hypoimmune platform, which might be capable of providing long-term durable responses, without immunosuppression being needed.
- 07/09/2023
|
Sana Biotechnology to Present at June 2023 Investor Conferences
- SEATTLE, May 31, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in June. The presentations will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer.
- 05/31/2023
|
7 High-Potential Penny Stocks in the Biotech Sector
- Most of the biggest biotech stocks on the market started off as unknown penny stocks. Look at Axsome Therapeutics (NASDAQ: AXSM ), for example.
- 05/04/2023
|
Sana Biotechnology to Present at May 2023 Investor Conferences
- SEATTLE, May 03, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in May. The presentations will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer and Nate Hardy, Sana's Chief Financial Officer.
- 05/03/2023
|
Wall Street Analysts Believe Sana (SANA) Could Rally 83.17%: Here's is How to Trade
- The average of price targets set by Wall Street analysts indicates a potential upside of 83.2% in Sana (SANA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 05/03/2023
|
The Top 3 Biotech Stocks to Watch in 2023
- Investors may want to keep an eye on the biotech boom and these top biotech stocks to watch. For one, the sector is still one of the safest, most recession-proof investments around.
- 04/20/2023
|
2 Growth Stocks That Jumped 42% and 58% Last Week: Can They Still Climb Higher?
- The week that ended April 14 was a good one for markets overall and a great one for two stocks in the healthcare sector. Sana Biotechnology jumped 58% higher last week as investors cheered preclinical results for its lead candidates.
- 04/17/2023
|
Why Shares of Sana Biotechnology Jumped This Week
- Sana Biotechnology is developing a cell-editing platform that it hopes will be able to avoid immune-system rejection. The company has no revenue but enough cash to fund operations into 2025, it said.
- 04/14/2023
|
Sana Biotechnology to Present at the Cowen 43rd Annual Health Care Conference
- SEATTLE, March 01, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentation at the Cowen 43rd Annual Health Care Conference at 9:50 a.m. ET on Wednesday, March 8, 2023. The presentation will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer.
- 03/01/2023
|
Sana Biotechnology: Time And Cash Burn Are The Enemies
- It's a challenging time for biotechs needing cash. Sana Biotechnology is such a company from the stable of Boston-based Flagship Pioneering.
- 02/08/2023
|
Sana Biotechnology A Buy On Low Price And First IND
- Sana had its first clinical trial cleared for initiation by the FDA in January. The current stock price is way below the 2021 IPO price.
- 02/08/2023
|
4 Penny Stocks To Watch With High Short Interest In January 2023
- Are these penny stocks ready to squeeze? The post 4 Penny Stocks To Watch With High Short Interest In January 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 01/27/2023
|
4 Short Squeeze Penny Stocks To Watch In January 2023; Time To Buy?
- Short squeeze penny stocks to watch this month. The post 4 Short Squeeze Penny Stocks To Watch In January 2023; Time To Buy?
- 01/13/2023
|
Sana Biotechnology to Present at the 41st Annual J.P. Morgan Healthcare Conference
- SEATTLE, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentation at the 41st Annual J.P. Morgan Healthcare Conference at 3:45 p.m. PT on Tuesday, January 10, 2023. The presentation will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer.
- 01/03/2023
|
7 Unknown Biotech Stocks That Could Rocket in 2023
- Investing in early-stage or unknown biotech stocks can be likened to investing in cryptocurrency projects. If the project developments are positive, returns can be multi-folds in a short time.
- 09/23/2022
|
Sana Biotechnology to Present at September 2022 Investor Conferences
- SEATTLE, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentations at two investor conferences in September. The presentations will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer.
- 09/09/2022
|
7 Stocks Due for a Stunning Short Squeeze
- Although the general rule of thumb is to avoid equities with heavy short interest, the new normal has brought with it new paradigms. One of these fresh approaches urges speculators to acquire short-squeeze stocks in an effort to move the equities higher, forcing the bears to cover their short positions.
- 08/09/2022
|
Sana Biotechnology A Buy For Potential Cancer Therapies
- Preclinical stage company has cash, expertise, and platform for success. Recent preclinical data showed potential of its technology.
- 06/27/2022
|
Sana Biotechnology to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
- SEATTLE, June 07, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentation at the Goldman Sachs 43rd Annual Global Healthcare Conference at 4:00 p.m. PT on Tuesday, June 14, 2022. The presentation will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer.
- 06/07/2022
|
Sana Biotechnology to build manufacturing in Seattle area, switching from California
- After announcing plans last summer to build its manufacturing facility in California, Sana Biotechnology has changed course.
- 06/01/2022
|
Sana Biotechnology to Present at the BofA Securities 2022 Healthcare Conference
- SEATTLE, May 04, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentation at the BofA Securities 2022 Healthcare Conference at 3:20 p.m. PT on Wednesday, May 11, 2022. The presentation will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer.
- 05/04/2022
|
Sana Biotechnology to Present Data from Multiple Preclinical Studies at the American Society of Gene and Cell Therapy 25th Annual Meeting
- SEATTLE, May 02, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that five abstracts covering preclinical data from its hypoimmune and fusogen platforms were accepted for either oral or poster presentation at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting taking place May 16-19, 2022 in Washington, D.C.
- 05/02/2022
|
Sana Biotechnology to Present at the 32nd Annual Oppenheimer Healthcare Conference
- SEATTLE, March 09, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentation at the 32nd Annual Oppenheimer Healthcare Conference at 6:20 a.m. PT on Wednesday, March 16, 2022. The presentation will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer.
- 03/09/2022
|
Sana Biotechnology to Present Preclinical Data on its Engineered Hypoimmune Allogeneic CAR T Cells at the 2022 American Association for Cancer Research Annual Meeting
- SEATTLE, March 08, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that preclinical data from its hypoimmune T cell program will be presented at the 2022 American Association for Cancer Research (AACR) Annual Meeting taking place April 8-13, 2022 in New Orleans, LA.
- 03/08/2022
|
Biotech IPOs Have Slowed to a Snail's Pace
- Sana Biotechnology Inc. ( SANA , Financial) and Lyel Immunopharma Inc. ( LYEL , Financial) are poster children for what's happening in the biotech initial public offering market. The two companies raised a combined total of $1 billion in 2021 and at one point had valuations exceeding a combined $5 billion.
- 02/17/2022
|
Sana Biotechnology: Exciting Preclinical Science
- Sana Biotechnology: Exciting Preclinical Science
- 02/12/2022
|
3 Biotechs That Will Soar Regardless of COVID-19
- In the healthcare markets, much time and energy have been focused on COVID-19. But there are some amazing opportunities outside the COVID space.
- 01/27/2022
|
Sana Biotechnology to Present at the 40th Annual J.P. Morgan Healthcare Conference
- SEATTLE, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentation at the 40th Annual J.P. Morgan Healthcare Conference at 10:30 a.m. PT on Tuesday, January 11, 2022. The presentation will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer.
- 01/04/2022
|
Sana Biotechnology to Present Pre-Clinical Data at 2021 American Society of Hematology Annual Meeting
- SEATTLE, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that data will be presented during four poster presentations at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, to be held both in person in Atlanta, GA and virtually from Sunday, December 11 to Tuesday, December 14, 2021.
- 11/04/2021
|
Sana Biotechnology inks $50M deal for precise gene editing system from Beam Therapeutics
- Sana Biotechnology has a new $50 million tool in its toolbox.
- 10/19/2021
|
Sana Biotechnology Obtains a Non-Exclusive License to CRISPR Cas12b Gene Editing Technology from Beam Therapeutics to Enable Engineered Cell Programs
- Agreement combines Beam's gene editing technology with Sana's ex vivo platform
- 10/19/2021
|
Sana Biotechnology to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
- SEATTLE, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentation at the Morgan Stanley 19th Annual Global Healthcare Conference at 2:00 p.m. PT on Monday, September 13, 2021. The presentation will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer.
- 09/07/2021
|
Week 34 MDA Breakout Stocks - August 2021: Short-Term Picks To Give You An Edge
- Two new Breakout Stocks for Week 34 with better than 10% short-term upside potential. The ETF/ETN forecast section now goes out in a separate article. Following the Momentum Gauges® the portfolio is up +49.8% YTD with a record 19 out of 33 weeks this year in negative signal conditions above the 40 MG level.
- 08/23/2021
|
Sana Biotechnology Enters Long-Term Lease to Establish Manufacturing Facility to Enable Its Gene and Cell Therapy Product Candidates
- Facility to Support Allogeneic CAR T, Gene Therapy, and Stem Cell-Derived Therapies
- 07/14/2021
|
Sana Biotechnology: Hypoimmune Cell Therapies
- Sana is the category leader for hypoimmune cell therapies that has the potential to transform diseases from oncology to CNS disorders and liver disease. Early data is promising, showing Sana's ability to design cells that can evade the host immune system and unlocking new therapeutic applications.
- 06/30/2021
|
Sana Biotechnology Presents Data at ISSCR 2021 Virtual Annual Meeting Showing Survival of Transplanted Hypoimmune Stem Cells Without Immunosuppression in Non-Human Primates
- First demonstration of the survival of allogeneic iPSCs transplanted into an immunocompetent non-human primate model without the need for immune suppression
- 06/26/2021
|
Sana Biotechnology to Present During Plenary Sessions at ISSCR 2021 Virtual Annual Meeting
- SEATTLE , June 14, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that data will be presented during two plenary sessions at the International Society for Stem Cell Research 2021 Virtual Annual Meeting, to be held Monday, June 21 through Saturday, June 26.
- 06/14/2021
|
Sana Biotechnology to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
- SEATTLE, June 02, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentation at the Goldman Sachs 42nd Annual Global Healthcare Conference at 12:00 p.m. PT on Wednesday, June 9, 2021. The presentation will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer.
- 06/02/2021
|
Sana Biotechnology Reports First Quarter 2021 Financial Results and Business Updates
- Presented key proof of concept data for multiple platforms at AACR 2021
- 05/05/2021
|
Sana Biotechnology to Present Pre-Clinical Data at American Society of Gene & Cell Therapy Annual Meeting 2021
- — Fusogen platform demonstrates potential for cell-specific in vivo delivery of gene therapies to multiple cell types, including T cells and hepatocytes —
- 04/27/2021
|
Sana Biotechnology Reports Fourth Quarter and 2020 Financial Results and Business Updates
- Expects to present data at multiple scientific conferences in 2021
- 03/24/2021
|
Regenerative Medicine Attracted Record $20 Billion in Funding in 2020
- Cell and gene therapy companies are quickly emerging as favorites of venture capital firms, investors and members of Big Pharma, according to a report from the Alliance for Regenerative Medicine.
- 03/23/2021
|
FUJIFILM Cellular Dynamics and Sana Biotechnology Announce License Agreement for the Development of iPSC-Derived Cell Therapies
- MADISON, Wis. and SEATTLE, March 17, 2021 (GLOBE NEWSWIRE) -- FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem cells (iPSC) technologies, and Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, announced today that Sana has been granted a non-exclusive right to use FUJIFILM Cellular Dynamics' iPSC platform for the development of commercial cell therapies. As a treatment modality, cell therapies have the potential to augment, repair, or replace human biology, including organs, tissues and cells.
- 03/17/2021
|
Sana Biotechnology: An Ultra-Risky Bet
- A bet on Sana is essentially a bet on management given that all the company's drugs are in the preclinical stage. As the example of Juno shows, though the company may be a winning proposition in the near term, success in terms of drug development is far from guaranteed.
- 02/08/2021
|
Sana Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
- SEATTLE, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA), a company focused on creating and delivering engineered cells as medicines, today announced the closing of its upsized initial public offering of 27,025,000 shares of its common stock at a public offering price of $25.00 per share, which includes the full exercise by the underwriters of their option to purchase 3,525,000 additional shares of common stock. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Sana, were approximately $675.6 million. All of the shares of common stock were offered by Sana. Sana's common stock is listed on The Nasdaq Global Select Market under the ticker symbol “SANA.”
- 02/08/2021
|
U.S. IPO Weekly Recap: Biotechs Flood The IPO Market In A 14 IPO Week
- The IPO market had its busiest week yet this year with 14 IPOs raising $3.9 billion and 27 SPACs raising $9.2 billion. German chemicals group Atotech downsized and priced below the range to raise $498 million at a $3.3 billion market cap.
- 02/08/2021
|
A Busy Day for Biotech IPOs
- Three biotechs—Sana Biotechnology, Landos Biopharma, Sensei Biotherapeutics—and chemicals specialist Atotech made their public-market debut Thursday. Here's how they fared.
- 02/04/2021
|
Sana joins Nasdaq with blockbuster $587M IPO
- Sana Biotechnology raised $587.
- 02/04/2021
|
Sana Announces Upsized Pricing of Initial Public Offering
- SEATTLE, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Sana) (Nasdaq: SANA), a company focused on creating and delivering engineered cells as medicines, today announced the pricing of its upsized initial public offering of 23,500,000 shares of its common stock at a public offering price of $25.00 per share. All of the shares of common stock are being offered by Sana. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Sana, are expected to be $587.5 million. Sana's common stock is expected to begin trading on The Nasdaq Global Select Market on February 4, 2021, under the ticker symbol “SANA.” The offering is expected to close on February 8, 2021, subject to the satisfaction of customary closing conditions. In addition, Sana has granted the underwriters a 30-day option to purchase up to an additional 3,525,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions, and, if exercised in full, would result in aggregate gross proceeds of approximately $675.6 million.
- 02/03/2021
|
